0001493152-17-012612.txt : 20171108 0001493152-17-012612.hdr.sgml : 20171108 20171108170119 ACCESSION NUMBER: 0001493152-17-012612 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171108 DATE AS OF CHANGE: 20171108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cocrystal Pharma, Inc. CENTRAL INDEX KEY: 0001412486 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 352528215 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55158 FILM NUMBER: 171187365 BUSINESS ADDRESS: STREET 1: 1860 MONTREAL ROAD CITY: TUCKER STATE: GA ZIP: 30084 BUSINESS PHONE: (425) 398-7178 MAIL ADDRESS: STREET 1: 1860 MONTREAL ROAD CITY: TUCKER STATE: GA ZIP: 30084 FORMER COMPANY: FORMER CONFORMED NAME: BIOZONE PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20110304 FORMER COMPANY: FORMER CONFORMED NAME: International Surf Resorts, Inc. DATE OF NAME CHANGE: 20070917 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

[X]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2017

 

OR

 

[  ]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission file number: 000-55158

 

COCRYSTAL PHARMA, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   35-2528215

(State or Other Jurisdiction of

Incorporation or Organization)

  

(I.R.S. Employer

Identification No.)

 

1860 Montreal Road    
Tucker, Georgia   30084
(Address of Principal Executive Offices)   (Zip Code)

 

(678)-892-8800

(Registrant’s Telephone Number, Including Area Code)

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No[  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Sec.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b2 of the Exchange Act.

 

Large accelerated filer [  ] Accelerated filer [X]
Non-accelerated filer [  ] Smaller reporting company [  ]
(Do not check if a smaller reporting company) Emerging growth company [  ]

 

If an emerging growth company, indicate by checkmark if the registrant has not elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

As of November 4, 2017, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 728,238,508.

 

 

 

 

 

 

COCRYSTAL PHARMA, INC.

 

FORM 10-Q FOR THE QUARTER ENDED September 30, 2017

 

INDEX

 

Part I - FINANCIAL INFORMATION F-1
Item 1. Financial Statements (Unaudited) F-1
  Condensed Consolidated Balance Sheets as of September 30, 2017 and December 31, 2016 F-1
  Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine months ended September 30, 2017 and 2016 F-2
  Condensed Consolidated Statement of Stockholders’ Equity for the Nine Months Ended September 30, 2017 F-3
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 F-4
  Notes to the Condensed Consolidated Financial Statements F-5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 1
Item 3. Quantitative and Qualitative Disclosures About Market Risk 5
Item 4. Controls and Procedures 5
Part II - OTHER INFORMATION 6
Item 1. Legal Proceedings 6
Item 1.A. Risk Factors 6
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 6
Item 3. Defaults Upon Senior Securities 6
Item 4. Mine Safety Disclosures 6
Item 5. Other 6
Item 6. Exhibits 6
SIGNATURES 7

  

i

 

 

Part I – FINANCIAL INFORMATION

Cocrystal Pharma, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

 

   September 30, 2017   December 31, 2016 
   (unaudited)     
Assets          
Current assets:          
Cash and cash equivalents  $1,345   $3,640 
Accounts receivable   -    21 
Prepaid expenses and other current assets   240    517 
Mortgage note receivable, current portion   1,294    1,294 
Total current assets   2,879    5,472 
           
Property and equipment, net   243    280 
Deposits   31    31 
In process research and development   53,905    53,905 
Goodwill   65,195    65,195 
Total assets  $122,253   $124,883 
           
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable and accrued expenses  $901   $563 
Derivative liabilities   855    1,476 
Total current liabilities   1,756    2,039 
Long-term liabilities          
Deferred rent   37    63 
Deferred tax liability   20,462    20,462 
Total long-term liabilities   20,499    20,525 
           
Total liabilities   22,255    22,564 
           
Commitments and contingencies          
           
Stockholders’ equity:          
Common stock, $0.001 par value; 800,000 shares authorized; 728,239 and 714,032 issued and outstanding as of September 30, 2017 and December 31, 2016, respectively   728    714 
Additional paid-in capital   242,510    239,035 
Accumulated deficit   (143,240)   (137,430)
Total stockholders’ equity   99,998    102,319 
           
Total liabilities and stockholders’ equity  $122,253   $124,883 

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

 

  F-1 

 

 

Cocrystal Pharma, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(unaudited)

(in thousands)

 

  

Three months ended

September 30,

  

Nine months ended

September 30,

 
    2017    2016    2017    2016 
Operating expenses                
Research and development  $1,393   $2,093   $

4,718

   $7,803 
General and administrative   717    (199)   

1,712

    3,630 
Total operating expenses   2,110    1,894    6,430    11,433 
                     
Loss from operations   (2,110)   (1,894)   (6,430)   (11,433)
                     
Other income (expense)                    
Interest income (expense), net   (2)   51    (1)   141 
Change in fair value of derivative liabilities   (148)   (38)   621    2,173 
Other income (expense), net   -    -    -    (1)
Total other income (expense), net   (150)   13    620    2,313 
                     
Loss before income taxes   (2,260)   (1,881)   (5,810)   (9,120)
                     
Income tax expense   -    -    -    - 
                     
Net loss and comprehensive loss  $(2,260)  $(1,881)  $(5,810)  $(9,120))
                     
Net loss per common share:                    
Loss per share, basic  $(0.00)  $(0.00)  $(0.01)  $(0.01)
Weighted average common shares outstanding, basic   728,032    707,478    720,284    702,634 
                     
Loss per share, fully diluted  $(0.00)  $(0.00)  $(0.01)  $(0.02)
Weighted average common shares outstanding, diluted   728,032    707,478    720,284    703,417 

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

 

  F-2 

 

 

Cocrystal Pharma, Inc.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

(unaudited)

(in thousands)

 

   Common Stock   Additional   Accumulated   Total Stockholders’ 
   Shares   Amount   Paid in capital   Deficit   Equity 
Balance as of December 31, 2016   714,032   $714   $239,035   $(137,430)  $102,319 
                          
Exercise of common stock options   1,707    2    78    -    80 
Stock-based compensation   -    -    409    -    409 
Sale of common shares   12,500    12    2,988    -    3,000 
Net loss   -    -    -    (5,810)   (5,810)
Balance as of September 30, 2017   728,239   $728   $242,510   $(143,240)  $99,998 

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

 

  F-3 

 

 

Cocrystal Pharma, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

 

   Nine months ended
September 30,		 
   2017   2016 
Net loss  $(5,810)  $(9,120)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   77    159 
Stock-based compensation   409    297 
Change in fair value of derivative liabilities   (621)   (2,173)
Change in deferred rent   (14)   (7)
Changes in operating assets and liabilities:          
Accounts receivable   21    16 
Prepaid expenses and other current assets   277    (184)
Accounts payable and accrued expenses   338    (1,342)
Net cash used in operating activities   (5,323)   (12,354)
           
Investing activities          
Purchase of fixed assets   (40)   (49)
Long-term deposits   (12)   (23)
Principal payments received on mortgage note receivable        40 
Net cash used in investing activities   (52)   (32)
           
Financing activities          
Proceeds from issuance of common stock and warrants   3,000    9,013 
Proceeds from exercise of stock options   80    3 
Net cash provided by financing activities   3,080    9,016 
           
Net decrease in cash and cash equivalents   (2,295)   (3,370)
Cash and cash equivalents at beginning of period   3,640    9,276 
Cash and cash equivalents at end of period  $1,345   $5,906 
           
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Cashless exercise of warrants  $-   $35 

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

 

  F-4 

 

 

Cocrystal Pharma, Inc.

Notes to the Condensed Consolidated Financial Statements

September 30, 2017

(unaudited)

 

Note 1- Organization and Significant Accounting Policies

 

The Company

 

Cocrystal Pharma, Inc. (“the Company”) is a biotechnology company that develops novel medicines for use in the treatment of human viral diseases. Cocrystal has developed proprietary structure-based drug design technology and antiviral nucleoside chemistry to create antiviral drug candidates. Our focus is to pursue the development and commercialization of broad-spectrum antiviral drug candidates designed to transform the treatment and/or prophylaxis of hepatitis C virus, influenza virus and norovirus. By concentrating our research and development efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas.

 

Cocrystal Pharma, Inc. was formerly incorporated in Nevada under the name Biozone Pharmaceuticals, Inc. On January 2, 2014, Biozone Pharmaceuticals, Inc. sold substantially all of its assets to MusclePharm Corporation (“MusclePharm”), and, on the same day, merged with Cocrystal Discovery, Inc. (“Discovery”) in a transaction accounted for as a reverse merger. Following the merger, the Company assumed Discovery’s business plan and operations. On March 18, 2014, the Company reincorporated in Delaware under the name Cocrystal Pharma, Inc.

 

Effective November 25, 2014, Cocrystal Pharma, Inc. and affiliated entities completed a series of merger transactions as a result of which Cocrystal Pharma, Inc. merged with RFS Pharma, LLC, a Georgia limited liability company (“RFS Pharma”). We refer to the surviving entity of this merger as “Cocrystal” or the “Company.”

 

The Company operates in only one segment. Management uses cash flow as the primary measure to manage its business and does not segment its business for internal reporting or decision-making.

 

The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs, obtaining regulatory approvals of its products and, ultimately, achieving profitable operations are dependent on, among other things, its ability to access potential markets, securing financing, attracting, retaining and motivating qualified personnel, and developing strategic alliances. Through September 30, 2017, the Company has funded its operations through equity offerings.

 

As of September 30, 2017, the Company had an accumulated deficit of $143.2 million. During the three and nine month periods ended September 30, 2017, the Company had losses from operations of $2.1 million and $6.4 million, respectively. Cash used in operating activities was approximately $5.3 million for the nine months ended September 30, 2017. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its drug development activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The Company expects to continue to incur substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases.

 

Basis of Presentation and Significant Accounting Policies

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. Operating results for the nine month period ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 or any future interim periods. All intercompany accounts and transactions have been eliminated in consolidation.

 

  F-5 

 

 

These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in the Cocrystal Pharma, Inc. Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the U.S. Securities and Exchange Commission (“SEC”). The accompanying condensed consolidated balance sheet as of September 30, 2017 has been derived from the audited financial statements as of that date, but does not include all of the information and notes required by GAAP.  The Company has evaluated subsequent events after the balance sheet date of September 30, 2017 through the date it has filed these unaudited condensed consolidated financial statements with the SEC and has disclosed all events or transactions that would require recognition or disclosures in these unaudited condensed consolidated financial statements.

 

Our significant accounting policies and practices are presented in Note 2 to the financial statements included in the Form 10-K.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

 

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). ASU 2016-02 impacts any entity that enters into a lease with some specified scope exceptions. This new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The guidance updates and supersedes Topic 840, Leases. For public entities, ASU 2016-02 is effective for fiscal years, and interim periods with those years, beginning after December 15, 2018, and early adoption is permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company has not yet implemented this guidance. However, based on the Company’s current operating lease arrangements, the Company does not expect the adoption of this standard to have a material impact on its financial statements based upon current obligations.

 

In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718). This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The Company adopted this standard as of January 1, 2017. The Company has elected to adopt the provisions of ASU No. 2016-09 that allow for stock option forfeitures to be recorded as they occur; however, adoption of this provision had no impact on its consolidated financial statements.

 

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). This standard addresses the classification of eight specific cash flow issues with the objective of reducing the existing diversity in practice. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.

 

In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350). This standard simplifies how an entity is required to test for goodwill impairment. ASU 2017-04 will be effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, with early adoption permitted after January 1, 2017. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.

 

  F-6 

 

 

In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company has not yet determined when it will adopt the provisions of this Update and has not yet determined the impact on its consolidated financial statements upon adoption.

 

Note 2 – Fair Value Measurements

 

FASB Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

 

Level 1 — quoted prices in active markets for identical assets or liabilities.

  

Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

  

Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

 

The Company categorized its cash equivalents as Level 1 fair value measurements.   The Company categorized its warrants potentially settleable in cash as Level 3 fair value measurements. The warrants potentially settleable in cash are measured at fair value on a recurring basis and are being marked to fair value at each reporting date until they are completely settled or meet the requirements to be accounted for as component of stockholders’ equity. The warrants are valued using the Black-Scholes option-pricing model as discussed in Note 4 below.

 

  F-7 

 

 

The following table presents a summary of fair values of assets and liabilities that are re-measured at fair value at each balance sheet date as of September 30, 2017 and December 31, 2016, and their placement within the fair value hierarchy as discussed above (in thousands):

 

     

Quoted

Prices in

Active

Markets

  

Significant

Other

Observable

Inputs

  

Unobservable

Inputs

 
Description  September 30, 2017   (Level 1)   (Level 2)   (Level 3) 
Assets:                    
Cash and cash equivalents  $1,345   $1,345   $       -   $         - 
Total assets  $1,345   $1,345   $-   $- 
                     
Liabilities:                    
Warrants potentially settleable in cash  $855   $-   $-   $855 
Total liabilities  $855   $-   $-   $855 

 

      Quoted Prices in Active Markets  

Significant

Other
Observable Inputs

   Unobservable Inputs 
Description  December 31, 2016   (Level 1)   (Level 2)   (Level 3) 
Assets:                    
Cash and cash equivalents  $3,640   $3,640   $     -   $        - 
Total assets  $3,640   $3,640   $-   $- 
                     
Liabilities:                    
Warrants potentially settleable in cash  $1,476   $-   $-   $1,476 
Total liabilities  $1,476   $-   $-   $1,476 

 

The Company has not transferred any financial instruments into or out of Level 3 classification during the nine months ended September 30, 2017 or 2016. A reconciliation of the beginning and ending Level 3 liabilities for the nine months ended September 30, 2017 and 2016 is as follows:

 

  

Fair Value Measurements
Using Significant Unobservable

Inputs
(Level 3)

 
   September 30, 2017   September 30, 2016 
Balance, January 1,  $1,476   $4,115 
Estimated fair value of warrants exchanged for common shares   -    (35)
Change in fair value of warrants   (621)   (2,173)
Balance at September 30, 2017 and 2016  $855   $1,907 

 

Note 3 – Stockholders’ equity

 

Common Stock — The Company has authorized up to 800,000,000 shares of common stock, $0.001 par value per share, and had 728,238,507 shares issued and outstanding as of September 30, 2017.

 

On April 20, 2017, the Company closed on proceeds of $3,000,000 in a private placement offering of 12,500,000 shares of the Company’s common stock at a purchase price of $0.24 per share to three accredited investors, which included Chairman Dr. Raymond F. Schinazi and OPKO Health, Inc., of which the Company’s director Dr. Phillip Frost is Chairman and Chief Executive Officer.

 

  F-8 

 

 

Shares of common stock authorized for future issuance as follows as of September 30, 2017 (in thousands):

 

   As of
September 30, 2017		 
Stock options issued and outstanding   21,344 
Authorized for future option grants   49,668 
Warrants outstanding   6,275 
Total   77,287 

 

The common stock authorized for future option grants was not reserved by the Company. The Company currently does not have enough common stock authorized to issue all the options authorized by the Company for future grants.

 

Note 4 – Warrants

 

The following is a summary of activity in the number of warrants outstanding to purchase the Company’s common stock for the nine months ended September 30, 2017 (in thousands):

 

  

Warrants accounted for

as: Equity

  

Warrants accounted for as:

Liabilities

 
   April 2013
warrants		   October 2013
Series A
warrants		   January 2014
warrants		   Total 
                 
Outstanding, December 31, 2016   1,500    775    4,000    6,275 
                     
Warrants expired   -    -    -    - 
Warrants exercised   -    -    -    - 
Outstanding, September 30, 2017   1,500    775    4,000    6,275 
Expiration
date		   

April 25, 2018

    October 24, 2023    January 16, 2024      

 

Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.

 

Warrants classified as liabilities

 

Liability-classified warrants consist of warrants issued in connection with equity financings in October 2013 and January 2014 and potentially settleable in cash and were determined not to be indexed to the Company’s own stock and are therefore accounted for as liabilities.

 

The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of comprehensive loss as changes in fair value of derivative liabilities.

 

The Company’s expected volatility is based on a combination of implied volatilities of similar publicly traded entities given that the Company has limited history of its own observable stock price. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the balance sheet date. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.

  F-9 

 

 

The fair value of the warrants classified as liabilities is estimated using the Black-Scholes option-pricing model with the following inputs as of September 30, 2017:

 

   October 2013 warrants   January 2014 warrants 
         
Strike price  $0.50   $0.50 
           
Expected term (years)   6.1    6.3 
Cumulative volatility %   88.00%   89.00%
Risk-free rate %   2.11%   2.12%

 

The Company’s expected volatility is based on a combination of implied volatilities of similar publicly traded entities as well as including the Company's own common stock volatility, given that the Company has limited history of its own observable stock price. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the balance sheet date. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.

 

Warrants classified as equity

 

Warrants that were recorded in equity at fair value upon issuance, and are not reported as liabilities on the balance sheet, are included in the above table which shows all warrants.

 

Note 5 – Stock-based compensation

 

The Company recorded approximately $142,000 and $409,000 of stock-based compensation related to employee stock options for the three and nine months ended September 30, 2017. For the three and nine months ended September 30, 2016, stock option expense was a ($1,138,000) and $297,000, respectively. During the third quarter of 2016, the Company reversed $1,392,000 in stock option expenses related to non-vested options issued to two executives that left the organization. Expense for the remaining employees were only $254,000, resulting in the negative stock option expense for the three months ended September 30, 2016.

 

As of September 30, 2017, there was $643,000 of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the Company’s operating expenses over a weighted average period of 1.50 years.

 

The administrator of the Company’s stock option plans determines the times when an option may become exercisable at the time of grant. Vesting periods of options granted to date have not exceeded five years. The options generally will expire, unless previously exercised, no later than ten years from the grant date. The Company is using unissued shares for all shares issued for options and restricted share awards.

 

  F-10 

 

 

The following schedule presents activity in the Company’s outstanding stock options for the nine months ended September 30, 2017 (in thousands, except per share amounts):

 

  

Number of shares available

for grant

  

Total

options outstanding

  

Weighted Average Exercise

Price

  

Aggregate Intrinsic

Value

 
Balance at December 31, 2016   48,368    24,351   $0.30   $5,457 
Exercised   -    (1,707)   0.05    - 
Granted   -    -    -    - 
Cancelled   1,300    (1,300)   0.96      
Balance at September 30, 2017   49,668    21,344   $0.28   $2,874 

 

As of September 30, 2017, options to purchase 21,344,222 shares of common stock, with an aggregate intrinsic value of $2,874,000, were outstanding that were fully vested or expected to vest with a weighted average remaining contractual term of 4.1 years. As of September 30, 2017, options to purchase 20,464,222 shares of common stock with a weighted average exercise price of $0.24 per share and a weighted average remaining contractual term of 3.6 years were fully vested with an intrinsic value of $2,874,000.

 

The aggregate intrinsic value of outstanding and exercisable options at September 30, 2017 was calculated based on the closing price of the Company’s common stock as reported on the OTCQB market on September 29, 2017 of $0.27 per share less the exercise price of the options. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Company’s common stock and the exercise price of the underlying options.

 

Note 6 – Net Loss per Share

 

The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260, Earnings Per Share. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. 

 

The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands):

 

   For the three months ended
September 30		   For the nine months ended
September 30		 
   2017   2016   2017   2016 
Options to purchase common stock   21,344    24,651    21,344    24,651 
Warrants to purchase common stock   6,275    -    6,275    783 
Total   27,619    24,651    27,619    25,434 

 

Note 7 - Mortgage Note Receivable

 

In June 2014, the Company acquired a mortgage note from a bank for $2,626,290 which is collateralized by, among other things, the underlying real estate and related improvements. The property subject to the mortgage is owned by an entity managed by Daniel Fisher, one of the founders of Biozone, and to the Company’s knowledge, is currently being occupied by Flavor Producers, Inc. in an instance where that company is not currently making rent payments. At September 30, 2017, the carrying amount of the mortgage note receivable was $1,294,000, consisting entirely of principal. The mortgage note has a maturity date of August 1, 2032 and bears an interest rate of 7.24%.

 

  F-11 

 

 

In 2014, Daniel Fisher and his affiliate, 580 Garcia Properties LLC, brought multiple lawsuits against the Company involving its predecessors and subsidiaries. The lawsuits have been settled and the complaints initiating them dismissed, without the Company making any payments to either Mr. Fisher or 580 Garcia Properties LLC. In addition, the mortgage note discussed above is a promissory note secured by a deed of trust under which 580 Garcia Properties LLC is the primary obligor. As of the time of the acquisition by the Company of the promissory note, 580 Garcia Properties LLC, was delinquent in its obligation to make certain monthly payments thereunder. Consequently, in December 2015, the Company issued notice of default letters to 580 Garcia Properties LLC, Daniel Fisher, and Sharon Fisher for said delinquencies, and proceeded in accordance with rights of a secured real estate creditor under California law, to initiate private foreclosure proceedings respecting the property, to foreclose under the promissory note secured by the deed of trust. A foreclosure sale was set in accordance with California law for January 27, 2017. Prior to the date of this foreclosure sale, Mr. Fisher filed a motion where he sought among other things an order of the court enjoining the foreclosure sale, alleging wrongdoing by the Company and Biozone Pharmaceuticals, Inc. and others that Mr. Fisher claims the Company has direct responsibility over. The court in the Fisher/Biozone Lawsuit heard oral argument on Mr. Fisher’s motion on March 2, 2017. On March 23, 2017, the court ordered further briefing by March 30, 2017 on the issue of whether to enjoin the foreclosure sale. On April 5, 2017, the court in the Fisher/Biozone Lawsuit entered a preliminary injunction barring the foreclosure sale until further order, and since that time the Company has engaged in settlement discussions with Mr. Fisher and 580 Garcia Properties LLC and others, to discuss an overall resolution of Fisher/Biozone claims of money damages allegedly caused to it by the transfer of occupants at the property, and Company efforts to either bring the promissory note to a performing status or to otherwise monetize the Company’s rights under the promissory note. The Company cannot offer any assurances as to when, or if, any settlement will be achieved, and the court has scheduled case management conferences to consider further proceedings, with the next case management conference set for November 30, 2017.

 

Because the Company intended to foreclose on the property and foreclosure was probable, in December 2016 the Company recognized an impairment on the mortgage note receivable of $1,176,000 to adjust the carrying value of the note to its fair value. The fair value of the note was determined by reference to the estimated fair value of the underlying property, which was determined based on analysis of comparable properties and recent market data. Furthermore, as a result of the Company’s plan to divest of this asset within the next twelve months, we are no longer recording interest income and the asset was reclassified from long-term to current at December 31, 2016.

 

Note 8 – Income Taxes

 

Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

 

As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. The Company has recorded a net deferred tax liability of $20,462,000 as of September 30, 2017 and December 31, 2016 as it has not considered the deferred tax liability, which is related to acquired in-process research and development, to be a future source of taxable income in evaluating the need for a valuation allowance against its deferred tax assets due to the in-process research and development asset being considered an indefinite-lived intangible asset.

 

FASB ASC Topic 740, Income Taxes (“ASC 740”), prescribes a recognition threshold and a measurement criterion for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be considered more likely than not to be sustained upon examination by taxing authorities. The Company records interest and penalties related to uncertain tax positions as a component of the provision for income taxes. As of September 30, 2017 and December 31, 2016, the Company had no unrecognized tax benefits.

 

The Company currently files income tax returns in the United States federal and various state jurisdictions. The Company is not currently under examination in any jurisdiction.

 

  F-12 

 

 

Note 9 - Contingencies

 

As a publicly traded company, from time to time, the Company may be party to, or otherwise involved in, legal proceedings and inquiries from regulators arising in the normal course of business. As of the date of this report, except as described below, the Company is not aware of any proceedings, threatened or pending, against it which, if determined adversely, would have a material effect on its business, results of operations, cash flows or financial position.

 

In June 2014, the Company acquired a mortgage note from a bank, which is collateralized by, among other things, the underlying real estate and related improvements. At September 30, 2017, the carrying amount of the mortgage note receivable was $1,294,000, consisting entirely of principal. The Company is currently in legal proceedings regarding the mortgage note receivable and collateralized real estate (see Note 7).

 

Note 10 - Transactions with Related Parties

 

Since November 2014, the Company has leased its Tucker, Georgia facility from a limited liability company owned by one of Cocrystal’s directors and principal shareholder, Dr. Raymond Schinazi. The annual expense for this lease is estimated to be $233,000. The present lease expired June 30, 2017 and the Company is currently on a month-to-month term. The total rent expense was $51,000 and $162,000 for the three and nine months ended September 30, 2017 and $59,000 and $177,000 for the three and nine months ended 2016, respectively.

 

Emory University: The Company has an exclusive license from Emory University for use of certain inventions and technology related to inhibitors of HCV that were jointly developed by Emory and Company employees. The License Agreement is dated March 7, 2013 wherein Emory agrees to add to the Licensed Patents and Licensed Technology Emory’s rights to any patent, patent application, invention, or technology application that is based on technology disclosed within three (3) years of March 7, 2013. The agreement includes payments due to Emory ranging from $40,000 to $500,000 based on successful achievement of certain drug development milestones. Additionally, the Company may have royalty payments at 3.5% of net sales due to Emory with a minimum in year one of $25,000 and increase to $400,000 in year five upon product commercialization. One of the Company’s Directors, Dr. Raymond Schinazi, is also a faculty member at Emory University and may share in these royalty payments with Emory.

 

On February 2, 2016, the Company entered into an agreement with Duke University and Emory University to license various patents and know-how to use CRISPR/Cas9 technologies for developing a possible cure for hepatitis B virus (HBV) and human papilloma virus (HPV). On September 25, 2017 (“Termination Date”), the Company mutually terminated the agreement with Duke University and there are no further rights or obligations under this license agreement after the Termination Date.

 

  F-13 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Overview

 

Cocrystal is a biotechnology company working to develop novel medicines for use in the treatment of human viral diseases. Cocrystal has developed proprietary structure-based drug design technology and antiviral nucleoside chemistry to create first-in-class and best-in-class antiviral drug candidates. Our focus is to pursue the development and commercialization of broad-spectrum antiviral drug candidates that will transform the treatment and/or prophylaxis of hepatitis C virus, norovirus, and influenza virus. By concentrating our research and development efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas.

 

Highlights

 

During the last nine months, the Company focused its research and development efforts primarily in three areas:

 

  ●

Hepatitis C. Our Hepatitis C Virus (“HCV”) Non-Nucleoside Polymerase Inhibitor CC-31244, is a potential best-in-class pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. It has the potential to be an important component in an all-oral ultra-short HCV combination therapy. CC-31244 showed an acceptable safety profile in both healthy volunteers and HCV-infected patients. There were no serious adverse events or discontinuations due to adverse events. The mean HCV viral load reduction was 3 logs at 48 hours and a sustained post-treatment antiviral effect after seven days of treatment. The Company is in partnership discussions for further clinical development of CC-31244.

     
  ●

Influenza. We have several preclinical candidates under development for the treatment of influenza infection. CC-42344, a novel PB2 inhibitor, has been selected as a preclinical lead. This candidate binds to a highly conserved PB2 site of influenza polymerase complex (PB1: PB2: PA), and exhibits a novel mechanism of action. CC-42344 showed excellent antiviral activity against influenza A strains, including avian pandemic strains and Tamiflu resistant strains, and has favorable pharmacokinetic profiles. We have initiated Investigational New Drug (“IND”) enabling studies this year.

     
  ●

Norovirus Infections. We continue to identify and develop nucleoside and non-nucleoside polymerase inhibitors.

 

1

 

 

Results of Operations for the Three and Nine months Ended September 30, 2017 compared to the Three and Nine months Ended September 30, 2016

 

Research and Development Expense

 

Research and development expense consists primarily of compensation-related costs for our employees dedicated to research and development activities and for our Scientific Advisory Board members, as well as lab supplies, lab services, and facilities and equipment costs. We expect research and development expenses to increase in future periods as we expand our clinical and pre-clinical development activities.

 

Total research and development expenses were approximately $1,393,000 for the three months ended September 30, 2017, compared with $2,093,000 for the three months ended September 30, 2016. The decrease of $700,000, or 33%, was due to the reduction in phase I clinical trials as these costs were primarily incurred during 2016.

 

Total research and development expenses were approximately $4,718,000 for the nine months ended September 30, 2017, compared with $7,803,000 for the nine months ended September 30, 2016. The decrease of $3,085,000 or 40%, was predominately due to the conclusion of phase I of clinical trials in 2016.

 

General and Administrative Expense

 

General and administrative expense includes compensation-related costs for our employees dedicated to general and administrative activities, legal fees, audit and tax fees, consultants and professional services, and general corporate expenses.

 

General and administrative expenses were $717,000 for the three months ended September 30, 2017, compared with negative expense of $199,000 for the three months ended September 30, 2016. This increase of $916,000, was primarily the result of the negative general and administrative expense for the three months ended September 30, 2016. This negative expense was due to reversal of stock-based compensation expense associated with options that were forfeited by two of the Company’s executives that left the organization during the quarter which had not vested. Because we assumed a zero forfeiture rate and none of these options had vested prior to forfeiture, expense associated with these options that had been recorded in previous periods was reversed during the three months ended September 30, 2016.

 

General and administrative expenses were approximately $1,712,000 for the nine months ended September 30, 2017, compared with $3,630,000 for the nine months ended September 30, 2016. The decrease of $1,918,000, or 53%, was due to an insurance reimbursement of prior legal costs, a non-cash reversal of stock compensation expense related to unvested options for the former General Council and Interim CFO that left the Company during 2017, a decrease in compensation costs due to staffing turnover, and a general decrease in legal costs.

 

Interest Income/Expense

 

For the three months and nine months ended September 30, 2017, the Company had interest expense of $2,000 and $1,000, respectively. Conversely, for the three months and nine months ended September 30, 2016, the Company had interest income of $51,000 and $141,000, respectively. These amounts represent interest earned on the mortgage note the Company acquired in June 2014. The key objectives of our investment policy are to preserve principal and ensure sufficient liquidity, so our invested cash may not earn as high a level of income as longer-term or higher risk securities, which generally have less liquidity and more volatility.

 

2

 

 

Other Income/Expense

 

For the three months ended September 30, 2017 and 2016, the Company had total other income (expense), net, of ($150,000) and $13,000, respectively. For the nine months ended September 30, 2017 and 2016, the Company had other income, net, totaling $620,000 and $2,313,000, respectively. Other income (expense) consists primarily of the change in fair value of the outstanding warrants to purchase our common stock that are accounted for as liabilities. Under accounting principles generally accepted in the United States, we record other income or expense for the change in fair value of our outstanding warrants that are accounted for as liabilities during each reporting period. If the fair value of the warrants decreases during the period, we record other income. The fair value of our outstanding warrants is inversely related to the fair value of the underlying common stock; as such, a decrease in the fair value of our common stock during a given period generally results in other income while an increase in the fair value of our common stock results in other expense. This other income or expense is non-cash. We believe investors should focus on our operating loss rather than net loss for the periods presented. Our operating loss for the three and nine months ended September 30, 2017 was $2,110,000 and $6,430,000, respectively, compared to $1,894,000 and $11,433,000 for the same periods in 2016, respectively.

 

Income Taxes

 

As a result of our cumulative losses, we have concluded that a full valuation allowance against our net deferred tax assets is appropriate. We have recorded a net deferred tax liability of $20,462,000 as of September 30, 2017 and December 31, 2016 as we have not considered the deferred tax liability, which is related to acquired in-process research and development, to be a future source of taxable income in evaluating the need for a valuation allowance against our deferred tax assets due to the in-process research and development asset being considered an indefinite-lived intangible asset.

 

Net Loss

 

As a result of the above factors, for the three and nine months ended September 30, 2017, we had a net loss of $2,260,000 and $5,810,000 compared to a net loss of $1,881,000 and $9,120,000 for the same periods in 2016.

 

Liquidity and Capital Resources

 

Net cash used in operating activities was $5,323,000 for the nine months ended September 30, 2017 compared to $12,354,000 for the same period in 2016. For the nine months ended September 30, 2016, net cash used by operating activities consisted primarily of $5,810,000 in operating expenses net of changes in operating assets and liabilities.

 

Net cash used in investing activities was $52,000 for the nine months ended September 30, 2017 compared to $32,000 for the same period in 2016. For the nine months ended September 30, 2017, net cash used for investing activities consisted primarily of capital spending of $40,000 and the payment of long-term deposits of $12,000. For the nine months ended September 30, 2016, net cash used for investing activities of $32,000 consisted mostly of capital spending totaling $49,000 and payment of long-term deposits of $23,000, net of $40,000 in principal payments received on our mortgage note receivable.

 

Net cash provided by financing activities was $3,080,000 for the nine months ended September 30, 2016 compared to cash provided by financing activities of $9,016,000 for the same period in 2016. For the nine months ended September 30, 2017, cash provided by financing activities resulted from our sale of common stock, which resulted in proceeds of $3,000,000 and $80,000 from the exercising of stock options. Net cash provided by financing activities for the nine months ended September 30, 2016 amounted to approximately $9,013,000 in proceeds from sale of our common stock and $3,000 for the exercise of stock options.

 

3

 

 

We have a history of operating losses as we have focused our efforts on raising capital and research and development activities. The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the U.S. applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has never been profitable, has no products approved for sale, has not generated any revenues to date from product sales, and has incurred significant operating losses and negative operating cash flows since inception. For the nine months ended September 30, 2017, the Company recorded a net loss of approximately $5.8 million and used approximately $5.3 million of cash for operating activities.

 

As of September 30, 2017, the Company had $1.3 million in cash to fund its operations. The Company does not believe its current cash balances will be sufficient to allow the Company to fund its operating plan for the next twelve months. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its drug development activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.

 

As the Company continues to incur losses, achieving profitability is dependent upon the successful development, approval and commercialization of its product candidates, and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital. Management intends to fund future operations through additional private or public equity offerings. The Company continues to engage in preliminary discussions with potential investors and broker-dealers but no terms have been agreed upon. There can be no assurances, however, that additional funding will be available on terms acceptable to the Company, or at all. Any equity financing may be dilutive to existing shareholders.

 

Tabular Disclosure of Contractual Obligations

 

Contractual Obligations ($ in thousands)  Payments due by period 
    

Less than

1 year

    

1-3 years

    

3-5 years

    

More than 5 years

 
Operating Lease Obligations  $224   $56   $-   $- 

 

Cautionary Note Regarding Forward-Looking Statements

 

This report includes forward-looking statements including statements regarding our drug development activities, future equity offering, cash flow deficit and liquidity. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

 

The results anticipated by any or all of these forward-looking statements might not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include the continued strength of the market for bio pharma equity offerings, unanticipated events which adversely affect the timing and success of our regulatory filings, failure to develop products which are deemed safe and effective and other issues which affect our ability to commercialize our product candidates. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2016. We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.

 

4

 

 

Critical Accounting Policies and Estimates

 

In our Annual Report on Form 10-K for the year ended December 31, 2016, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. There have been no changes to these policies since December 31, 2016. Readers are encouraged to review these disclosures in conjunction with the review of this report.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

There has been no material change in our assessment of sensitivity to market risk since our presentation set forth in Item 7A “Quantitative and Qualitative Disclosures about Market Risk” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the Securities and Exchange Commission. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, management concluded that our disclosure controls and procedures were not effective as of September 30, 2017 at the reasonable assurance level.

 

Changes to the Company’s Internal Control Over Financial Reporting

 

The following changes that occurred during the nine months ended September 30, 2017 have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

On January 24, 2017, Curtis Dale, Interim Chief Financial Officer, tendered his resignation, at which time the Company initiated a search for a qualified replacement.

 

On February 12, 2017, Walt A. Linscott informed the Board of the Company of his resignation as General Counsel and Secretary of the Company, effective March 1, 2017.

 

On February 23, 2017, James Martin was appointed to serve as the Interim Chief Financial Officer. Mr. Martin has extensive experience in accounting and finance, as well as significant pharmaceutical industry knowledge.

 

During the year ended December 31, 2016, we concluded there were material weaknesses in the design and operating effectiveness of our internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. With the oversight of senior management and our audit committee, we took additional measures to remediate the underlying causes of the material weaknesses. During the year ended December 31, 2016, we worked with a third-party consultant to assist our management team in addressing the underlying cause of the material weaknesses primarily through the documentation of improved processes and documented procedures, which were designed and implemented by our management team. Management concluded that certain previously identified material weaknesses were not completely remediated as of December 31, 2016. Progress in addressing material weaknesses has also recently been hampered by the timing of the turnover in our management team, as described above, during the first quarter of 2017 and the effect of such timing on the transition of responsibilities related to the execution of control activities. Therefore, we identified several material weaknesses that still existed as of December 31, 2016 and which were reported in our Annual Report on Form 10-K for the year ended December 31, 2016, filed on March 30, 2017.

 

We have begun procedures to enhance our internal control and are in the process of designing and implementing enhanced internal control to address these material weaknesses. After these enhanced internal control processes are implemented, we plan to test these controls to determine whether they are operating effectively and whether we can conclude that the material weaknesses previously identified have been remediated. The material weaknesses previously identified cannot be considered remediated until the controls have operated for a sufficient period of time and until management has concluded that the controls are operating effectively. Our goal is to remediate the material weaknesses by the end of 2017.

 

5

 

 

PART II — OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, the Company is a party to, or otherwise involved in, legal proceedings arising in the normal course of business. During the quarter ended September 30, 2017, there were no material developments to our previously reported legal proceedings except the following:

 

In 2014, Daniel Fisher and his affiliate, 580 Garcia Properties LLC, brought multiple lawsuits against the Company involving its predecessors and subsidiaries. The lawsuits have been settled and the complaints initiating them dismissed, without the Company making any payments to either Mr. Fisher or 580 Garcia Properties LLC. In addition, the mortgage note discussed above is a promissory note secured by a deed of trust under which 580 Garcia Properties LLC is the primary obligor. As of the time of the acquisition by the Company of the promissory note, 580 Garcia Properties LLC, was delinquent in its obligation to make certain monthly payments thereunder. Consequently, in December 2015, the Company issued notice of default letters to 580 Garcia Properties LLC, Daniel Fisher, and Sharon Fisher for said delinquencies, and proceeded in accordance with rights of a secured real estate creditor under California law, to initiate private foreclosure proceedings respecting the property, to foreclose under the promissory note secured by the deed of trust. A foreclosure sale was set in accordance with California law for January 27, 2017. Prior to the date of this foreclosure sale, Mr. Fisher filed a motion where he sought among other things an order of the court enjoining the foreclosure sale, alleging wrongdoing by the Company and Biozone Pharmaceuticals, Inc. and others that Mr. Fisher claims the Company has direct responsibility over. The court in the Fisher/Biozone Lawsuit heard oral argument on Mr. Fisher’s motion on March 2, 2017. On March 23, 2017, the court ordered further briefing by March 30, 2017 on the issue of whether to enjoin the foreclosure sale. On April 5, 2017, the court in the Fisher/Biozone Lawsuit entered a preliminary injunction barring the foreclosure sale until further order, and since that time the Company has engaged in settlement discussions with Mr. Fisher and 580 Garcia Properties LLC and others, to discuss an overall resolution of Fisher/Biozone claims of money damages allegedly caused to it by the transfer of occupants at the property, and Company efforts to either bring the promissory note to a performing status or to otherwise monetize the Company’s rights under the promissory note. The Company cannot offer any assurances as to when, or if, any settlement will be achieved, and the court has scheduled case management conferences to consider further proceedings, with the next case management conference set for November 30, 2017.

 

ITEM 1.A RISK FACTORS

 

None

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

All recent sales of unregistered securities have been previously reported.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not Applicable

 

ITEM 5. OTHER

 

None

 

ITEM 6. EXHIBITS

 

The exhibits listed in the accompanying “Index to Exhibits” are filed or incorporated by reference as part of this Form 10-Q.

 

6

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Cocrystal Pharma, Inc.
     
Dated: November 8, 2017 By: /s/Gary Wilcox
   

Gary Wilcox

Interim Chief Executive Officer

(Principal Executive Officer)

 
Dated: November 8, 2017 By: /s/ James Martin
   

Chief Financial Officer

(Principal Financial Officer)

 

7

 

 

EXHIBIT INDEX

 

    Incorporated by Reference
Exhibit No.   Exhibit Description   Form   Date   Number   Filed or Furnished Herewith
3.1   Certificate of Incorporation, as amended   10-K   3/31/15   3.1    
3.2   Amended and Restated Bylaws   8-K   12/1/14   3.6    
10.1   James Martin Consulting Agreement*   8-K   2/24/17   10.1    
10.2   Form of Securities Purchase Agreement dated April 20, 2017   8-K   4/24/17   10.1    
10.3   James Martin Offer Letter date May 26, 2017   8-K   6/1/17   10.1    
31.1   Certification of Principal Executive Officer (302)               Filed
31.2   Certification of Principal Financial Officer (302)               Filed
32.1   Certification of Principal Executive Officer and Principal Financial Officer (906)               Furnished**
101.INS   XBRL Instance Document               Filed
101.SCH   XBRL Taxonomy Extension Schema Document               Filed
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document               Filed
101.LAB   XBRL Taxonomy Extension Label Linkbase Document               Filed
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document               Filed

 

* Represents management contracts or compensatory plan

 

** This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.

 

Copies of this report (including the financial statements) and any of the exhibits referred to above will be furnished at no cost to our shareholders who make a written request to our Corporate Secretary at Cocrystal Pharma, Inc., 1860 Montreal Road, Tucker GA 30084.

 

8

 

 

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

 

I, Gary Wilcox, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Cocrystal Pharma, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 8, 2017

 

/s/ Gary Wilcox  

Gary Wilcox

Interim Chief Executive Officer

(Principal Executive Officer)

  

 

 

 

 

 EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

 

I, James J. Martin, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Cocrystal Pharma, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 8, 2017

 

/s/ James J. Martin  

 

 

 

 

 EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of Cocrystal Pharma, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof, I, Gary Wilcox, certify, pursuant to 18 U.S.C. Sec.1350, as adopted pursuant to Sec.906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

1. The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

 

2. The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Gary Wilcox  

Gary Wilcox

Interim Chief Executive Officer

(Principal Executive Officer)

  

 

Dated: November 8, 2017

 

In connection with the quarterly report of Cocrystal Pharma, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof, I, James Martin, certify, pursuant to 18 U.S.C. Sec.1350, as adopted pursuant to Sec.906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

1. The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

 

2. The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ James J. Martin  
James Martin  
Chief Financial Officer  
(Principal Financial Officer)  
   
Dated: November 8, 2017  

 

 

 

 

 EX-101.INS 5 cocp-20170930.xml XBRL INSTANCE FILE 0001412486 2017-01-01 2017-09-30 0001412486 2016-09-30 0001412486 2016-12-31 0001412486 2017-09-30 0001412486 us-gaap:CommonStockMember 2016-12-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001412486 us-gaap:RetainedEarningsMember 2016-12-31 0001412486 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001412486 COCP:MortgageNoteMember 2014-06-30 0001412486 COCP:MortgageNoteMember 2014-09-01 2014-09-30 0001412486 us-gaap:WarrantMember 2016-12-31 0001412486 COCP:OctoberTwoThousandThirteenSeriesAWarrantsMember COCP:LiabilitiesMember 2016-12-31 0001412486 COCP:AprilTwoThousandThirteenWarrantsMember us-gaap:EquityMember 2016-12-31 0001412486 COCP:OctoberTwoThousandThirteenWarrantsMember 2017-01-01 2017-09-30 0001412486 COCP:JanuaryTwoThousandFourteenWarrantsMember 2017-01-01 2017-09-30 0001412486 COCP:OctoberTwoThousandThirteenWarrantsMember 2017-09-30 0001412486 COCP:JanuaryTwoThousandFourteenWarrantsMember 2017-09-30 0001412486 us-gaap:FairValueInputsLevel1Member 2016-12-31 0001412486 us-gaap:FairValueInputsLevel2Member 2016-12-31 0001412486 us-gaap:FairValueInputsLevel3Member 2016-12-31 0001412486 us-gaap:FairValueInputsLevel3Member 2015-12-31 0001412486 us-gaap:FairValueInputsLevel3Member 2016-01-01 2016-09-30 0001412486 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001412486 COCP:AprilTwoThousandThirteenWarrantsMember us-gaap:EquityMember 2017-01-01 2017-09-30 0001412486 COCP:OctoberTwoThousandThirteenSeriesAWarrantsMember COCP:LiabilitiesMember 2017-01-01 2017-09-30 0001412486 COCP:JanuaryTwoThousandFourteenWarrantsMember COCP:LiabilitiesMember 2017-01-01 2017-09-30 0001412486 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001412486 us-gaap:PrivatePlacementMember COCP:ThreeAccreditedInvestorMember 2017-04-20 0001412486 2016-01-01 2016-09-30 0001412486 2016-07-01 2016-09-30 0001412486 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001412486 us-gaap:CommonStockMember 2017-09-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001412486 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0001412486 us-gaap:RetainedEarningsMember 2017-09-30 0001412486 2015-12-31 0001412486 us-gaap:FairValueInputsLevel3Member 2017-01-01 2017-09-30 0001412486 us-gaap:FairValueInputsLevel1Member 2017-09-30 0001412486 us-gaap:FairValueInputsLevel2Member 2017-09-30 0001412486 us-gaap:FairValueInputsLevel3Member 2017-09-30 0001412486 us-gaap:FairValueInputsLevel3Member 2016-09-30 0001412486 COCP:AprilTwoThousandThirteenWarrantsMember us-gaap:EquityMember 2017-09-30 0001412486 COCP:OctoberTwoThousandThirteenSeriesAWarrantsMember COCP:LiabilitiesMember 2017-09-30 0001412486 COCP:JanuaryTwoThousandFourteenWarrantsMember COCP:LiabilitiesMember 2017-09-30 0001412486 us-gaap:WarrantMember 2017-09-30 0001412486 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001412486 COCP:DrRaymondSchinaziMember 2014-11-30 0001412486 COCP:DrRaymondSchinaziMember 2014-11-01 2014-11-30 0001412486 us-gaap:MinimumMember COCP:LicenseAgreementMember 2017-09-30 0001412486 us-gaap:MaximumMember COCP:LicenseAgreementMember 2017-09-30 0001412486 COCP:OneYearMember COCP:LicenseAgreementMember 2017-09-30 0001412486 COCP:FiveYearMember COCP:LicenseAgreementMember 2017-09-30 0001412486 us-gaap:PrivatePlacementMember COCP:ThreeAccreditedInvestorMember 2017-04-19 2017-04-20 0001412486 COCP:JanuaryTwoThousandFourteenWarrantsMember COCP:LiabilitiesMember 2016-12-31 0001412486 2017-07-01 2017-09-30 0001412486 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001412486 us-gaap:WarrantMember 2017-07-01 2017-09-30 0001412486 us-gaap:WarrantMember 2016-07-01 2016-09-30 0001412486 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001412486 2017-11-04 0001412486 COCP:TwoExecutivesMember 2016-01-01 2016-09-30 0001412486 COCP:EmployeesMember 2016-07-01 2016-09-30 0001412486 COCP:MortgageNoteMember 2016-12-01 2016-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Cocrystal Pharma, Inc. 10-Q 2017-09-30 false --12-31 2017 5906000 3640000 1345000 3640000 9276000 1345000 124883000 122253000 22564000 22255000 102319000 99998000 714000 239035000 -137430000 728000 242510000 -143240000 0.001 0.001 800000000 800000000 714032000 728239000 714032000 728239000 -5810000 -9120000 -1881000 -5810000 -2260000 -1707000 1707000 714032000 728239000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3 &#8211; Stockholders&#8217; equity</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Common Stock &#8212; The Company has authorized up to 800,000,000 shares of common stock, $0.001 par value per share, and had 728,238,507 shares issued and outstanding as of September 30, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 20, 2017, the Company closed on proceeds of $3,000,000 in a private placement offering of 12,500,000 shares of the Company&#8217;s common stock at a purchase price of $0.24 per share to three accredited investors, which included Chairman Dr. Raymond F. Schinazi and OPKO Health, Inc., of which the Company&#8217;s director Dr. Phillip Frost is Chairman and Chief Executive Officer.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares of common stock authorized for future issuance as follows as of September 30, 2017 (in thousands):</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">As of&#160;</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">September 30, 2017</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock options issued and outstanding</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,344</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Authorized for future option grants</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">49,668</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,275</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">77,287</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The common stock authorized for future option grants was not reserved by the Company. The Company currently does not have enough common stock authorized to issue all the options authorized by the Company for future grants.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8211; Fair Value Measurements</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB Accounting Standards Codification (&#8220;ASC&#8221;) 820 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 &#8212; quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 &#8212; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 &#8212; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company categorized its cash equivalents as Level 1 fair value measurements. &#160;&#160;The Company categorized its warrants potentially settleable in cash as Level 3 fair value measurements. The warrants potentially settleable in cash are measured at fair value on a recurring basis and are being marked to fair value at each reporting date until they are completely settled or meet the requirements to be accounted for as component of stockholders&#8217; equity. The warrants are valued using the Black-Scholes option-pricing model as discussed in Note 4 below.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents a summary of fair values of assets and liabilities that are re-measured at fair value at each balance sheet date as of September 30, 2017 and December 31, 2016, and their placement within the fair value hierarchy as discussed above (in thousands):</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Quoted</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Prices in</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Active</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Markets</p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Significant</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Other</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Observable</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Inputs</p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Unobservable</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Inputs</p></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Description</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">September 30, 2017</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Level 1)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Level 2)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Level 3)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Assets:</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 42%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,345</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,345</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,345</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,345</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Liabilities:</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants potentially settleable in cash</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">855</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">855</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total liabilities</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">855</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">855</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Quoted Prices in Active Markets</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Significant</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Other&#160;<br /> Observable Inputs</p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Unobservable Inputs</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Description</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2016</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Level 1)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Level 2)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Level 3)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Assets:</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 42%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,640</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,640</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,640</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,640</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Liabilities:</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants potentially settleable in cash</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,476</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,476</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total liabilities</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,476</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,476</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has not transferred any financial instruments into or out of Level 3 classification during the nine months ended September 30, 2017 or 2016. A reconciliation of the beginning and ending Level 3 liabilities for the nine months ended September 30, 2017 and 2016 is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Fair Value Measurements&#160;<br /> Using Significant Unobservable</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Inputs&#160;<br /> (Level 3)</p></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">September 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">September 30, 2016</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance, January 1,</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,476</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,115</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Estimated fair value of warrants exchanged for common shares</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(35</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Change in fair value of warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(621</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(2,173</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2017 and 2016</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">855</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,907</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6 &#8211; Net Loss per Share</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260,&#160;<i>Earnings Per Share</i>. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants.&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands):</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">For the three months ended</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">September 30</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">For the nine months ended</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">September 30</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options to purchase common stock</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,344</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,651</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,344</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,651</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants to purchase common stock</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,275</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,275</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">783</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">27,619</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,651</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">27,619</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,434</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">N<b>ote 8 &#8211; Income Taxes</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the Company&#8217;s cumulative losses, management has concluded that a full valuation allowance against the Company&#8217;s net deferred tax assets is appropriate. The Company has recorded a net deferred tax liability of $20,462,000 as of September 30, 2017 and December 31, 2016 as it has not considered the deferred tax liability, which is related to acquired in-process research and development, to be a future source of taxable income in evaluating the need for a valuation allowance against its deferred tax assets due to the in-process research and development asset being considered an indefinite-lived intangible asset.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB ASC Topic 740,&#160;<i>Income Taxes</i>&#160;(&#8220;ASC 740&#8221;), prescribes a recognition threshold and a measurement criterion for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be considered more likely than not to be sustained upon examination by taxing authorities. The Company records interest and penalties related to uncertain tax positions as a component of the provision for income taxes. As of September 30, 2017 and December 31, 2016, the Company had no unrecognized tax benefits.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently files income tax returns in the United States federal and various state jurisdictions. The Company is not currently under examination in any jurisdiction.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8211; Warrants</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of activity in the number of warrants outstanding to purchase the Company&#8217;s common stock for the nine months ended September 30, 2017 (in thousands):</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Warrants accounted for</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>as: Equity</b></p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="10" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Warrants accounted for as:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Liabilities</b></p></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">April 2013&#160;</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">warrants</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 2013&#160;</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Series A&#160;</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">warrants</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">January 2014&#160;</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">warrants</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 25%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding, December 31, 2016</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 21%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">775</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,275</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants expired</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants exercised</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">775</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,275</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expiration&#160;</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">date</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">April 25, 2018</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 24, 2023</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">January 16, 2024</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Warrants classified as liabilities</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Liability-classified warrants consist of warrants issued in connection with equity financings in October 2013 and January 2014 and potentially settleable in cash and were determined not to be indexed to the Company&#8217;s own stock and are therefore accounted for as liabilities.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of comprehensive loss as changes in fair value of derivative liabilities.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s expected volatility is based on a combination of implied volatilities of similar publicly traded entities given that the Company has limited history of its own observable stock price. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the balance sheet date. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the warrants classified as liabilities is estimated using the Black-Scholes option-pricing model with the following inputs as of September 30, 2017:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 2013 warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">January 2014 warrants</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Strike price</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected term (years)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6.1</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6.3</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cumulative volatility %</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">88.00</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">89.00</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free rate %</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.11</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.12</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s expected volatility is based on a combination of implied volatilities of similar publicly traded entities as well as including the Company's own common stock volatility, given that the Company has limited history of its own observable stock price. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the balance sheet date. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Warrants classified as equity</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Warrants that were recorded in equity at fair value upon issuance, and are not reported as liabilities on the balance sheet, are included in the above table which shows all warrants.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> P6Y1M6D P6Y3M19D 3000000 12000 2988000 3000000 12500000 12500000 0.00 0.8800 0.8900 0.00 0.0211 0.0212 2032-08-01 0.0724 2626290 77287000 49668000 48368000 49668000 2874000 5457000 2874000 0.30 0.28 P3Y7M6D 1300000 21344222 24351000 21344000 0.05 0.96 21344000 6275000 6275000 775000 1500000 1500000 775000 4000000 6275000 4000000 2018-04-25 2023-10-24 2024-01-16 0.27 0.50 0.50 1476000 855000 1476000 855000 1476000 4115000 855000 1907000 -2173000 -621000 27619000 783000 24651000 6275000 25434000 24651000 21344000 27619000 21344000 6275000 24651000 2017-06-30 0001412486 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following schedule presents activity in the Company&#8217;s outstanding stock options for the nine months ended September 30, 2017 (in thousands, except per share amounts):</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Number of shares available</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">for grant</p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Total</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">options outstanding</p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted Average Exercise</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Price</p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Aggregate Intrinsic</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Value</p></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2016</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">48,368</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,351</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.30</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,457</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,707</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.05</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,300</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,300</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.96</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">49,668</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,344</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.28</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,874</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of activity in the number of warrants outstanding to purchase the Company&#8217;s common stock for the nine months ended September 30, 2017 (in thousands):</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Warrants accounted for</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>as: Equity</b></p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="10" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Warrants accounted for as:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Liabilities</b></p></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">April 2013&#160;</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">warrants</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 2013&#160;</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Series A&#160;</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">warrants</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">January 2014&#160;</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">warrants</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 25%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding, December 31, 2016</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 21%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">775</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,275</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants expired</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants exercised</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">775</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,275</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expiration&#160;</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">date</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">April 25, 2018</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 24, 2023</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">January 16, 2024</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the warrants classified as liabilities is estimated using the Black-Scholes option-pricing model with the following inputs as of September 30, 2017:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 2013 warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">January 2014 warrants</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Strike price</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected term (years)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6.1</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6.3</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cumulative volatility %</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">88.00</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">89.00</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free rate %</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.11</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.12</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents a summary of fair values of assets and liabilities that are re-measured at fair value at each balance sheet date as of September 30, 2017 and December 31, 2016, and their placement within the fair value hierarchy as discussed above (in thousands):</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Quoted</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Prices in</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Active</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Markets</p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Significant</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Other</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Observable</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Inputs</p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Unobservable</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Inputs</p></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Description</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">September 30, 2017</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Level 1)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Level 2)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Level 3)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Assets:</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 42%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,345</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,345</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,345</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,345</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Liabilities:</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants potentially settleable in cash</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">855</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">855</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total liabilities</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">855</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">855</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Quoted Prices in Active Markets</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Significant</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Other&#160;<br /> Observable Inputs</p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Unobservable Inputs</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Description</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2016</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Level 1)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Level 2)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Level 3)</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Assets:</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 42%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,640</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,640</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,640</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,640</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Liabilities:</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants potentially settleable in cash</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,476</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,476</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total liabilities</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,476</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,476</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has not transferred any financial instruments into or out of Level 3 classification during the nine months ended September 30, 2017 or 2016. A reconciliation of the beginning and ending Level 3 liabilities for the nine months ended September 30, 2017 and 2016 is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Fair Value Measurements&#160;<br /> Using Significant Unobservable</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Inputs&#160;<br /> (Level 3)</p></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">September 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">September 30, 2016</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance, January 1,</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,476</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,115</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Estimated fair value of warrants exchanged for common shares</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(35</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Change in fair value of warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(621</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(2,173</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2017 and 2016</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">855</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,907</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands):</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">For the three months ended</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">September 30</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">For the nine months ended</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">September 30</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options to purchase common stock</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,344</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,651</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,344</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 9%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,651</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants to purchase common stock</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,275</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,275</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">783</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">27,619</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,651</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">27,619</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,434</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> COCP Q3 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1- Organization and Significant Accounting Policies</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>The Company</u></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Cocrystal Pharma, Inc. (&#8220;the Company&#8221;) is a biotechnology company that develops novel medicines for use in the treatment of human viral diseases. Cocrystal has developed proprietary structure-based drug design technology and antiviral nucleoside chemistry to create antiviral drug candidates. Our focus is to pursue the development and commercialization of broad-spectrum antiviral drug candidates designed to transform the treatment and/or prophylaxis of hepatitis C virus, influenza virus and norovirus. By concentrating our research and development efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Cocrystal Pharma, Inc. was formerly incorporated in Nevada under the name Biozone Pharmaceuticals, Inc. On January 2, 2014, Biozone Pharmaceuticals, Inc. sold substantially all of its assets to MusclePharm Corporation (&#8220;MusclePharm&#8221;), and, on the same day, merged with Cocrystal Discovery, Inc. (&#8220;Discovery&#8221;) in a transaction accounted for as a reverse merger. Following the merger, the Company assumed Discovery&#8217;s business plan and operations. On March 18, 2014, the Company reincorporated in Delaware under the name Cocrystal Pharma, Inc.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective November 25, 2014, Cocrystal Pharma, Inc. and affiliated entities completed a series of merger transactions as a result of which Cocrystal Pharma, Inc. merged with RFS Pharma, LLC, a Georgia limited liability company (&#8220;RFS Pharma&#8221;). We refer to the surviving entity of this merger as &#8220;Cocrystal&#8221; or the &#8220;Company.&#8221;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company operates in only one segment. Management uses cash flow as the primary measure to manage its business and does not segment its business for internal reporting or decision-making.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#8217;s development programs, obtaining regulatory approvals of its products and, ultimately, achieving profitable operations are dependent on, among other things, its ability to access potential markets, securing financing, attracting, retaining and motivating qualified personnel, and developing strategic alliances. Through September 30, 2017, the Company has funded its operations through equity offerings.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2017, the Company had an accumulated deficit of $143.2 million. During the three and nine month periods ended September 30, 2017, the Company had losses from operations of $2.1 million and $6.4 million, respectively. Cash used in operating activities was approximately $5.3 million for the nine months ended September 30, 2017. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its drug development activities. These conditions raise substantial doubt as to the Company&#8217;s ability to continue as a going concern. The Company expects to continue to incur substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis of Presentation and Significant Accounting Policies</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. Operating results for the nine month period ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 or any future interim periods. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in the Cocrystal Pharma, Inc. Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The accompanying condensed consolidated balance sheet as of September 30, 2017 has been derived from the audited financial statements as of that date, but does not include all of the information and notes required by GAAP.&#160;&#160;The Company has evaluated subsequent events after the balance sheet date of September 30, 2017 through the date it has filed these unaudited condensed consolidated financial statements with the SEC and has disclosed all events or transactions that would require recognition or disclosures in these unaudited condensed consolidated financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our significant accounting policies and practices are presented in Note 2 to the financial statements included in the Form 10-K.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02,&#160;<i>Leases&#160;</i>(<i>Topic 842</i>). ASU 2016-02 impacts any entity that enters into a lease with some specified scope exceptions. This new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The guidance updates and supersedes Topic 840,&#160;<i>Leases</i>. For public entities, ASU 2016-02 is effective for fiscal years, and interim periods with those years, beginning after December 15, 2018, and early adoption is permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company has not yet implemented this guidance. However, based on the Company&#8217;s current operating lease arrangements, the Company does not expect the adoption of this standard to have a material impact on its financial statements based upon current obligations.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2016, the FASB issued ASU No. 2016-09,&#160;<i>Compensation&#8212;Stock Compensation (Topic 718)</i>. This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The Company adopted this standard as of January 1, 2017. The Company has elected to adopt the provisions of ASU No. 2016-09 that allow for stock option forfeitures to be recorded as they occur; however, adoption of this provision had no impact on its consolidated financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU No. 2016-15,&#160;<i>Statement of Cash Flows (Topic 230)</i>. This standard addresses the classification of eight specific cash flow issues with the objective of reducing the existing diversity in practice. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2017, the FASB issued ASU No. 2017-04,&#160;<i>Intangibles - Goodwill and Other (Topic 350)</i>. This standard simplifies how an entity is required to test for goodwill impairment. ASU 2017-04 will be effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, with early adoption permitted after January 1, 2017. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the FASB issued ASU 2017-11,&#160;<i>Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</i>. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company has not yet determined when it will adopt the provisions of this Update and has not yet determined the impact on its consolidated financial statements upon adoption.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 10 - Transactions with Related Parties</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Since November 2014, the Company has leased its Tucker, Georgia facility from a limited liability company owned by one of Cocrystal&#8217;s directors and principal shareholder, Dr. Raymond Schinazi. The annual expense for this lease is estimated to be $233,000. The present lease expired June 30, 2017 and the Company is currently on a month-to-month term. The total rent expense was $51,000 and $162,000 for the three and nine months ended September 30, 2017 and $59,000 and $177,000 for the three and nine months ended 2016, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Emory University: The Company has an exclusive license from Emory University for use of certain inventions and technology related to inhibitors of HCV that were jointly developed by Emory and Company employees. The License Agreement is dated March 7, 2013 wherein Emory agrees to add to the Licensed Patents and Licensed Technology Emory&#8217;s rights to any patent, patent application, invention, or technology application that is based on technology disclosed within three (3) years of March 7, 2013. The agreement includes payments due to Emory ranging from $40,000 to $500,000 based on successful achievement of certain drug development milestones. Additionally, the Company may have royalty payments at 3.5% of net sales due to Emory with a minimum in year one of $25,000 and increase to $400,000 in year five upon product commercialization. One of the Company&#8217;s Directors, Dr. Raymond Schinazi, is also a faculty member at Emory University and may share in these royalty payments with Emory.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 2, 2016, the Company entered into an agreement with Duke University and Emory University to license various patents and know-how to use CRISPR/Cas9 technologies for developing a possible cure for hepatitis B virus (HBV) and human papilloma virus (HPV). On September 25, 2017 (&#8220;Termination Date&#8221;), the Company mutually terminated the agreement with Duke University and there are no further rights or obligations under this license agreement after the Termination Date.</p> -35000 P1Y6M P4Y1M6D <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Note 9 - Contingencies</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As a publicly traded company, from time to time, the Company may be party to, or otherwise involved in, legal proceedings and inquiries from regulators arising in the normal course of business. As of the date of this report, except as described below, the Company is not aware of any proceedings, threatened or pending, against it which, if determined adversely, would have a material effect on its business, results of operations, cash flows or financial position.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2014, the Company acquired a mortgage note from a bank, which is collateralized by, among other things, the underlying real estate and related improvements. At September 30, 2017, the carrying amount of the mortgage note receivable was $1,294,000, consisting entirely of principal. The Company is currently in legal proceedings regarding the mortgage note receivable and collateralized real estate (see Note 7).</p> 233000 40000 500000 25000 400000 0.035 Accelerated Filer <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 7 - Mortgage Note Receivable</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2014, the Company acquired a mortgage note from a bank for $2,626,290 which is collateralized by, among other things, the underlying real estate and related improvements. The property subject to the mortgage is owned by an entity managed by Daniel Fisher, one of the founders of Biozone, and to the Company&#8217;s knowledge, is currently being occupied by Flavor Producers, Inc. in an instance where that company is not currently making rent payments. At September 30, 2017, the carrying amount of the mortgage note receivable was $1,294,000, consisting entirely of principal. The mortgage note has a maturity date of August 1, 2032 and bears an interest rate of 7.24%.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2014, Daniel Fisher and his affiliate, 580 Garcia Properties LLC, brought multiple lawsuits against the Company involving its predecessors and subsidiaries. The lawsuits have been settled and the complaints initiating them dismissed, without the Company making any payments to either Mr. Fisher or 580 Garcia Properties LLC. In addition, the mortgage note discussed above is a promissory note secured by a deed of trust under which 580 Garcia Properties LLC is the primary obligor. As of the time of the acquisition by the Company of the promissory note, 580 Garcia Properties LLC, was delinquent in its obligation to make certain monthly payments thereunder. Consequently, in December 2015, the Company issued notice of default letters to 580 Garcia Properties LLC, Daniel Fisher, and Sharon Fisher for said delinquencies, and proceeded in accordance with rights of a secured real estate creditor under California law, to initiate private foreclosure proceedings respecting the property, to foreclose under the promissory note secured by the deed of trust. A foreclosure sale was set in accordance with California law for January 27, 2017. Prior to the date of this foreclosure sale, Mr. Fisher filed a motion where he sought among other things an order of the court enjoining the foreclosure sale, alleging wrongdoing by the Company and Biozone Pharmaceuticals, Inc. and others that Mr. Fisher claims the Company has direct responsibility over. The court in the Fisher/Biozone Lawsuit heard oral argument on Mr. Fisher&#8217;s motion on March 2, 2017. On March 23, 2017, the court ordered further briefing by March 30, 2017 on the issue of whether to enjoin the foreclosure sale. On April 5, 2017, the court in the Fisher/Biozone Lawsuit entered a preliminary injunction barring the foreclosure sale until further order, and since that time the Company has engaged in settlement discussions with Mr. Fisher and 580 Garcia Properties LLC and others, to discuss an overall resolution of Fisher/Biozone claims of money damages allegedly caused to it by the transfer of occupants at the property, and Company efforts to either bring the promissory note to a performing status or to otherwise monetize the Company&#8217;s rights under the promissory note. The Company cannot offer any assurances as to when, or if, any settlement will be achieved, and the court has scheduled case management conferences to consider further proceedings, with the next case management conference set for November 30, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Because the Company intended to foreclose on the property and foreclosure was probable, in December 2016 the Company recognized an impairment on the mortgage note receivable of $1,176,000 to adjust the carrying value of the note to its fair value. The fair value of the note was determined by reference to the estimated fair value of the underlying property, which was determined based on analysis of comparable properties and recent market data. Furthermore, as a result of the Company&#8217;s plan to divest of this asset within the next twelve months, we are no longer recording interest income and the asset was reclassified from long-term to current at December 31, 2016.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02,&#160;<i>Leases&#160;</i>(<i>Topic 842</i>). ASU 2016-02 impacts any entity that enters into a lease with some specified scope exceptions. This new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The guidance updates and supersedes Topic 840,&#160;<i>Leases</i>. For public entities, ASU 2016-02 is effective for fiscal years, and interim periods with those years, beginning after December 15, 2018, and early adoption is permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company has not yet implemented this guidance. However, based on the Company&#8217;s current operating lease arrangements, the Company does not expect the adoption of this standard to have a material impact on its financial statements based upon current obligations.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2016, the FASB issued ASU No. 2016-09,&#160;<i>Compensation&#8212;Stock Compensation (Topic 718)</i>. This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The Company adopted this standard as of January 1, 2017. The Company has elected to adopt the provisions of ASU No. 2016-09 that allow for stock option forfeitures to be recorded as they occur; however, adoption of this provision had no impact on its consolidated financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU No. 2016-15,&#160;<i>Statement of Cash Flows (Topic 230)</i>. This standard addresses the classification of eight specific cash flow issues with the objective of reducing the existing diversity in practice. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2017, the FASB issued ASU No. 2017-04,&#160;<i>Intangibles - Goodwill and Other (Topic 350)</i>. This standard simplifies how an entity is required to test for goodwill impairment. ASU 2017-04 will be effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, with early adoption permitted after January 1, 2017. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the FASB issued ASU 2017-11,&#160;<i>Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</i>. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company has not yet determined when it will adopt the provisions of this Update and has not yet determined the impact on its consolidated financial statements upon adoption.</p> 124883000 122253000 -137430000 -143240000 239035000 242510000 714000 728000 20525000 20499000 20462000 20462000 2039000 1756000 1476000 855000 65195000 65195000 53905000 53905000 31000 31000 280000 243000 5472000 2879000 1294000 1294000 517000 240000 21000 6430000 11433000 1894000 2110000 1712000 3630000 -199000 717000 4718000 7803000 2093000 1393000 -6430000 -11433000 -1894000 -2110000 -1000 141000 51000 -2000 621000 2173000 -38000 -148000 -0.01 -0.01 -0.00 -0.00 720284000 702634000 707478000 728032000 -0.01 -0.02 -0.00 -0.00 720284000 703417000 707478000 728032000 35000 -2295000 -3370000 3080000 9016000 80000 3000 3000000 9013000 -52000 -32000 -40000 40000 49000 -5323000 -12354000 338000 -1342000 -277000 184000 -21000 -16000 409000 297000 -1138000 142000 77000 159000 14000 7000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis of Presentation and Significant Accounting Policies</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. Operating results for the nine month period ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 or any future interim periods. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in the Cocrystal Pharma, Inc. Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The accompanying condensed consolidated balance sheet as of September 30, 2017 has been derived from the audited financial statements as of that date, but does not include all of the information and notes required by GAAP.&#160;&#160;The Company has evaluated subsequent events after the balance sheet date of September 30, 2017 through the date it has filed these unaudited condensed consolidated financial statements with the SEC and has disclosed all events or transactions that would require recognition or disclosures in these unaudited condensed consolidated financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our significant accounting policies and practices are presented in Note 2 to the financial statements included in the Form 10-K.</p> 162000 177000 59000 51000 -1300000 643000 2874000 0.24 -5810000 -9120000 -1881000 -2260000 12000 23000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8211; Stock-based compensation</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded approximately $142,000 and $409,000 of stock-based compensation related to employee stock options for the three and nine months ended September 30, 2017. For the three and nine months ended September 30, 2016, stock option expense was a ($1,138,000) and $297,000, respectively. During the third quarter of 2016, the Company reversed $1,392,000 in stock option expenses related to non-vested options issued to two executives that left the organization. Expense for the remaining employees were only $254,000, resulting in the negative stock option expense for the three months ended September 30, 2016.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2017, there was $643,000 of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted average period of 1.50 years.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The administrator of the Company&#8217;s stock option plans determines the times when an option may become exercisable at the time of grant. Vesting periods of options granted to date have not exceeded five years. The options generally will expire, unless previously exercised, no later than ten years from the grant date. The Company is using unissued shares for all shares issued for options and restricted share awards.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following schedule presents activity in the Company&#8217;s outstanding stock options for the nine months ended September 30, 2017 (in thousands, except per share amounts):</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Number of shares available</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">for grant</p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Total</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">options outstanding</p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted Average Exercise</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Price</p></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Aggregate Intrinsic</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Value</p></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2016</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">48,368</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,351</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.30</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,457</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,707</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.05</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,300</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,300</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.96</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2017</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">49,668</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,344</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.28</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,874</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2017, options to purchase 21,344,222 shares of common stock, with an aggregate intrinsic value of $2,874,000, were outstanding that were fully vested or expected to vest with a weighted average remaining contractual term of 4.1 years. As of September 30, 2017, options to purchase 20,464,222 shares of common stock with a weighted average exercise price of $0.24 per share and a weighted average remaining contractual term of 3.6 years were fully vested with an intrinsic value of $2,874,000.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value of outstanding and exercisable options at September 30, 2017 was calculated based on the closing price of the Company&#8217;s common stock as reported on the OTCQB market on September 29, 2017 of $0.27 per share less the exercise price of the options. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Company&#8217;s common stock and the exercise price of the underlying options.</p> 620000 2313000 13000 -150000 -1000 1392000 254000 563000 901000 63000 37000 80000 2000 78000 409000 409000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares of common stock authorized for future issuance as follows as of September 30, 2017 (in thousands):</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">As of&#160;</font><br /> <font style="font: 10pt Times New Roman, Times, Serif">September 30, 2017</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock options issued and outstanding</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,344</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Authorized for future option grants</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">49,668</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,275</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">77,287</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> 0.24 20464222 Vesting periods of options granted to date have not exceeded five years. The options generally will expire, unless previously exercised, no later than ten years from the grant date. 1176000 728238508 3640000 1345000 3640000 1345000 1476000 855000 1476000 855000 EX-101.SCH 6 cocp-20170930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Mortgage Note Receivable link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Transactions with Related Parties link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Organization and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Organization and Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Fair Value Measurement - Summary of Fair Values of Assets and Liabilities Measured at Fair Value On Recurring and NonRecurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Fair Value Measurements - Schedule of Reconciliation of the Beginning and Ending Level 3 Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stockholder's Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Authorized for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Warrants - Summary of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Warrants - Schedule of Fair Value of Warrants Classified as Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stock-Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculations of Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Mortgage Note Receivable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Transactions with Related Parties (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cocp-20170930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 cocp-20170930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 cocp-20170930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid in Capital [Member] Accumulated Deficit [Member] Warrants to Purchase Common Stock [Member] Debt Instrument [Axis] Mortgage Note [Member] Award Type [Axis] October 2013 Series A Warrants [Member] Trading Activity [Axis] Liabilities [Member] April 2013 Warrants [Member] Equity [Member] October 2013 Warrants [Member] January 2014 Warrants [Member] Fair Value, Hierarchy [Axis] Quoted Prices in Active Markets Level 1 [Member] Significant Other Observable Inputs Level 2 [Member] Unobservable Inputs Level 3 [Member] Options to Purchase Common Stock [Member] Sale of Stock [Axis] Private Placement [Member] Title of Individual [Axis] Three Accredited Investor [Member] Dr. Raymond Schinazi [Member] Range [Axis] Minimum [Member] Type of Arrangement and Non-arrangement Transactions [Axis] License Agreement [Member] Maximum [Member] One Year [Member] Five Year [Member] Two Executives [Member] Employees [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Accounts receivable Prepaid expenses and other current assets Mortgage note receivable, current portion Total current assets Property and equipment, net Deposits In process research and development Goodwill Total assets Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses Derivative liabilities Total current liabilities Long-term liabilities Deferred rent Deferred tax liability Total long-term liabilities Total liabilities Commitments and contingencies Stockholders' equity: Common stock, $0.001 par value; 800,000 shares authorized; 728,239 and 714,032 issued and outstanding as of September 30, 2017 and December 31, 2016, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses Research and development General and administrative Total operating expenses Loss from operations Other income (expense) Interest income (expense), net Change in fair value of derivative liabilities Other income (expense), net Total other income (expense), net Loss before income taxes Income tax expense Net loss and comprehensive loss Net loss per common share: Loss per share, basic Weighted average common shares outstanding, basic Loss per share, fully diluted Weighted average common shares outstanding, diluted Statement [Table] Statement [Line Items] Beginning balance Beginning balance, shares Exercise of common stock options Exercise of common stock options, shares Stock-based compensation Sale of common shares Sale of common shares, shares Net loss Ending Balance Ending Balance, shares Statement of Cash Flows [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Stock-based compensation Change in fair value of derivative liabilities Change in deferred rent Changes in operating assets and liabilities: Accounts receivable Prepaid expenses and other current assets Accounts payable and accrued expenses Net cash used in operating activities Investing activities Purchase of fixed assets Long-term deposits Principal payments received on mortgage note receivable Net cash used in investing activities Financing activities Proceeds from issuance of common stock and warrants Proceeds from exercise of stock options Net cash provided by financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Cashless exercise of warrants Accounting Policies [Abstract] Organization and Significant Accounting Policies Fair Value Disclosures [Abstract] Fair Value Measurements Equity [Abstract] Stockholders' Equity Warrants Warrants Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-Based Compensation Earnings Per Share [Abstract] Net Loss Per Share Receivables [Abstract] Mortgage Note Receivable Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Contingencies Related Party Transactions [Abstract] Transactions with Related Parties Basis of Presentation and Significant Accounting Policies Use of Estimates Recent Accounting Pronouncements Summary of Fair Values of Assets and Liabilities Measured at Fair Value on Recurring and NonRecurring Basis Schedule of Reconciliation of Beginning and Ending Level 3 Liabilities Schedule of Shares of Common Stock Authorized for Future Issuance Warrants Tables Summary of Warrant Activity Schedule of Fair Value of Warrants Classified as Liabilities Schedule of Share-based Compensation, Stock Options, Activity Schedule of Antidilutive Securities Excluded from Calculations of Net Loss Per Share Accumulated deficit Loss from operations Cash used in operating activities Total assets Warrants potentially settleable in cash Total liabilities Balance - January 1 Estimated fair value of warrants exchanged for common shares Change in fair value of warrants Balance at September 30, 2017 and 2016 Common stock authorized Common stock par value Common stock issued Common stock outstanding Number of common stock issued Number of common stock issued, shares Common stock purchase price, per share Stock options issued and outstanding Authorized for future option grants Warrants outstanding Total Risk free interest Dividend Yield Number of warrants outstanding, beginning Number of warrants expired Number of warrants exercised Number of warrants outstanding, ending Warrant expiration date Strike price Expected term (years) Cumulative volatility % Risk-free rate % Plan Name [Axis] Stock-based compensation related to employee Stock option expense Unrecognized compensation cost related to outstanding options Weighted average period Stock based compensation vesting description Stock option to purchase common stock vested or expected to vest Aggregate intrinsic value vested or expected to be vest Stock option vesting period Stock option to purchase common stock Weighted average exercise price Weighted average contractual term Aggregate intrinsic value Share price Number of shares available for grant, beginning Number of shares available for grant, Exercised Number of shares available for grant, Granted Number of shares available for grant, Cancelled Number of shares available for grant, ending Total options outstanding, beginning Total options outstanding, Exercised Total options outstanding, Granted Total options outstanding, Cancelled Total options outstanding, ending Weighted Average Exercise Price, outstanding Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Cancelled Weighted Average Exercise Price, ending Aggregate Intrinsic Value, outstanding Aggregate Intrinsic Value, ending Anti-dilutive securities Mortgage note receivable Mortgage note receivable Debt instrument maturity date Debt instrument interest rate Impairment of mortgage note receivable Net deferred tax liability Unrecognized tax benefits Carrying amount of mortgage note receivable Legal Entity [Axis] Annual lease expense Lease expiration Rent expenses Royalty payable Royalty payment rate Non-refundable license fee April 20, 2017 [Member] April 2013 Warrants [Member] August 2013 Warrants [Member] Biozone, Biozone Acquisitions Co., Inc [Member] Bothell [Member] California [Member] Cashless exercise of warrants. Change in fair value of warrants for the year ended. Cocrystal, Cocrystal Holdings, Inc [Member] Cocrystal Discovery [Member] Cocrystal Discovery Series A [Member] Computer And Office Equipment [Member] Duke [Member] Emory University [Member] Employee Stock Option Plan [Member] Employees Nonemployee Directors And Consultants [Member] Estimated fair value of warrants exchanged for common shares. February 2012 Warrants [Member] Federal [Member] impairment of mortgage note receivable. January 2015 Warrants [Member] January 2014 Warrants [Member] January 2012 Warrants [Member] Lab Equipment [Member] Liabilities [Member] March 10 2017 [Member] March 2013 Warrants [Member] Maximum In Five Year [Member] Minimum In One Year [Member] Mortgage Note [Member] Mortgage note receivable current. MusclePharm, Inc [Member] October 2013 Warrants Series A [Member] October 2013 Warrants [Member] October 2013 Warrants One [Member] Over-the-Counter Bulletin Board [Member] custom:PrincipalPaymentsReceivedOnMortgageNoteReceivable RFS Pharma, LLC [Member] Schedule Of Share Based Compensation Warrant Activity Disclosures [Table Text Block] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Stock options issued and outstanding. Tucker [Member] 2015 plan [Member] 2007 And 2015 plan [Member] 2007 Plan [Member] Warrant expiration date. Warrants Disclosure [Text Block] Equity Incentive Plans [Member] Annual lease expense. Royalty payment rate. Non-refundable license fee. Dr. Raymond Schinazi [Member] License Agreement [Member] One Year [Member] Five Year [Member] Three Accredited Investor [Member] Two Executives [Member] Employees [Member] Schedule Of Shares Of Common Stock Authorized For Future Issuance [Table Text Block] Assets, Current Assets [Default Label] Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Shares, Outstanding Increase (Decrease) in Deferred Charges Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Long-term Investments PrincipalPaymentsReceivedOnMortgageNoteReceivable Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) WarrantsDisclosureTextBlock Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price EX-101.PRE 10 cocp-20170930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2017
Nov. 04, 2017
Document And Entity Information    
Entity Registrant Name Cocrystal Pharma, Inc.  
Entity Central Index Key 0001412486  
Document Type 10-Q  
Document Period End Date Sep. 30, 2017  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   728,238,508
Trading Symbol COCP  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2017  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 1,345 $ 3,640
Accounts receivable 21
Prepaid expenses and other current assets 240 517
Mortgage note receivable, current portion 1,294 1,294
Total current assets 2,879 5,472
Property and equipment, net 243 280
Deposits 31 31
In process research and development 53,905 53,905
Goodwill 65,195 65,195
Total assets 122,253 124,883
Current liabilities:    
Accounts payable and accrued expenses 901 563
Derivative liabilities 855 1,476
Total current liabilities 1,756 2,039
Long-term liabilities    
Deferred rent 37 63
Deferred tax liability 20,462 20,462
Total long-term liabilities 20,499 20,525
Total liabilities 22,255 22,564
Commitments and contingencies
Stockholders' equity:    
Common stock, $0.001 par value; 800,000 shares authorized; 728,239 and 714,032 issued and outstanding as of September 30, 2017 and December 31, 2016, respectively 728 714
Additional paid-in capital 242,510 239,035
Accumulated deficit (143,240) (137,430)
Total stockholders' equity 99,998 102,319
Total liabilities and stockholders' equity $ 122,253 $ 124,883
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2017
Dec. 31, 2016
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 800,000,000 800,000,000
Common stock, shares issued 728,239,000 714,032,000
Common stock, shares outstanding 728,239,000 714,032,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Operating expenses        
Research and development $ 1,393 $ 2,093 $ 4,718 $ 7,803
General and administrative 717 (199) 1,712 3,630
Total operating expenses 2,110 1,894 6,430 11,433
Loss from operations (2,110) (1,894) (6,430) (11,433)
Other income (expense)        
Interest income (expense), net (2) 51 (1) 141
Change in fair value of derivative liabilities (148) (38) 621 2,173
Other income (expense), net (1)
Total other income (expense), net (150) 13 620 2,313
Loss before income taxes (2,260) (1,881) (5,810) (9,120)
Income tax expense
Net loss and comprehensive loss $ (2,260) $ (1,881) $ (5,810) $ (9,120)
Net loss per common share:        
Loss per share, basic $ (0.00) $ (0.00) $ (0.01) $ (0.01)
Weighted average common shares outstanding, basic 728,032,000 707,478,000 720,284,000 702,634,000
Loss per share, fully diluted $ (0.00) $ (0.00) $ (0.01) $ (0.02)
Weighted average common shares outstanding, diluted 728,032,000 707,478,000 720,284,000 703,417,000
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid in Capital [Member]
Accumulated Deficit [Member]
Total
Beginning balance at Dec. 31, 2016 $ 714 $ 239,035 $ (137,430) $ 102,319
Beginning balance, shares at Dec. 31, 2016 714,032,000      
Exercise of common stock options $ 2 78 80
Exercise of common stock options, shares 1,707,000      
Stock-based compensation 409 409
Sale of common shares $ 12 2,988 3,000
Sale of common shares, shares 12,500,000      
Net loss (5,810) (5,810)
Ending Balance at Sep. 30, 2017 $ 728 $ 242,510 $ (143,240) $ 99,998
Ending Balance, shares at Sep. 30, 2017 728,239,000      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Statement of Cash Flows [Abstract]    
Net loss $ (5,810) $ (9,120)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 77 159
Stock-based compensation 409 297
Change in fair value of derivative liabilities (621) (2,173)
Change in deferred rent (14) (7)
Changes in operating assets and liabilities:    
Accounts receivable 21 16
Prepaid expenses and other current assets 277 (184)
Accounts payable and accrued expenses 338 (1,342)
Net cash used in operating activities (5,323) (12,354)
Investing activities    
Purchase of fixed assets (40) (49)
Long-term deposits (12) (23)
Principal payments received on mortgage note receivable 40
Net cash used in investing activities (52) (32)
Financing activities    
Proceeds from issuance of common stock and warrants 3,000 9,013
Proceeds from exercise of stock options 80 3
Net cash provided by financing activities 3,080 9,016
Net decrease in cash and cash equivalents (2,295) (3,370)
Cash and cash equivalents at beginning of period 3,640 9,276
Cash and cash equivalents at end of period 1,345 5,906
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Cashless exercise of warrants $ 35
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization and Significant Accounting Policies
 9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Organization and Significant Accounting Policies

Note 1- Organization and Significant Accounting Policies

 

The Company

 

Cocrystal Pharma, Inc. (“the Company”) is a biotechnology company that develops novel medicines for use in the treatment of human viral diseases. Cocrystal has developed proprietary structure-based drug design technology and antiviral nucleoside chemistry to create antiviral drug candidates. Our focus is to pursue the development and commercialization of broad-spectrum antiviral drug candidates designed to transform the treatment and/or prophylaxis of hepatitis C virus, influenza virus and norovirus. By concentrating our research and development efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas.

 

Cocrystal Pharma, Inc. was formerly incorporated in Nevada under the name Biozone Pharmaceuticals, Inc. On January 2, 2014, Biozone Pharmaceuticals, Inc. sold substantially all of its assets to MusclePharm Corporation (“MusclePharm”), and, on the same day, merged with Cocrystal Discovery, Inc. (“Discovery”) in a transaction accounted for as a reverse merger. Following the merger, the Company assumed Discovery’s business plan and operations. On March 18, 2014, the Company reincorporated in Delaware under the name Cocrystal Pharma, Inc.

 

Effective November 25, 2014, Cocrystal Pharma, Inc. and affiliated entities completed a series of merger transactions as a result of which Cocrystal Pharma, Inc. merged with RFS Pharma, LLC, a Georgia limited liability company (“RFS Pharma”). We refer to the surviving entity of this merger as “Cocrystal” or the “Company.”

 

The Company operates in only one segment. Management uses cash flow as the primary measure to manage its business and does not segment its business for internal reporting or decision-making.

 

The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs, obtaining regulatory approvals of its products and, ultimately, achieving profitable operations are dependent on, among other things, its ability to access potential markets, securing financing, attracting, retaining and motivating qualified personnel, and developing strategic alliances. Through September 30, 2017, the Company has funded its operations through equity offerings.

 

As of September 30, 2017, the Company had an accumulated deficit of $143.2 million. During the three and nine month periods ended September 30, 2017, the Company had losses from operations of $2.1 million and $6.4 million, respectively. Cash used in operating activities was approximately $5.3 million for the nine months ended September 30, 2017. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that any additional capital that it is able to obtain, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its drug development activities. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The Company expects to continue to incur substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases.

 

Basis of Presentation and Significant Accounting Policies

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. Operating results for the nine month period ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 or any future interim periods. All intercompany accounts and transactions have been eliminated in consolidation.

 

These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in the Cocrystal Pharma, Inc. Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the U.S. Securities and Exchange Commission (“SEC”). The accompanying condensed consolidated balance sheet as of September 30, 2017 has been derived from the audited financial statements as of that date, but does not include all of the information and notes required by GAAP.  The Company has evaluated subsequent events after the balance sheet date of September 30, 2017 through the date it has filed these unaudited condensed consolidated financial statements with the SEC and has disclosed all events or transactions that would require recognition or disclosures in these unaudited condensed consolidated financial statements.

 

Our significant accounting policies and practices are presented in Note 2 to the financial statements included in the Form 10-K.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

 

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). ASU 2016-02 impacts any entity that enters into a lease with some specified scope exceptions. This new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The guidance updates and supersedes Topic 840, Leases. For public entities, ASU 2016-02 is effective for fiscal years, and interim periods with those years, beginning after December 15, 2018, and early adoption is permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company has not yet implemented this guidance. However, based on the Company’s current operating lease arrangements, the Company does not expect the adoption of this standard to have a material impact on its financial statements based upon current obligations.

 

In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718). This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The Company adopted this standard as of January 1, 2017. The Company has elected to adopt the provisions of ASU No. 2016-09 that allow for stock option forfeitures to be recorded as they occur; however, adoption of this provision had no impact on its consolidated financial statements.

 

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). This standard addresses the classification of eight specific cash flow issues with the objective of reducing the existing diversity in practice. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.

 

In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350). This standard simplifies how an entity is required to test for goodwill impairment. ASU 2017-04 will be effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, with early adoption permitted after January 1, 2017. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.

 

In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company has not yet determined when it will adopt the provisions of this Update and has not yet determined the impact on its consolidated financial statements upon adoption.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 2 – Fair Value Measurements

 

FASB Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

 

Level 1 — quoted prices in active markets for identical assets or liabilities.

  

Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

  

Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

 

The Company categorized its cash equivalents as Level 1 fair value measurements.   The Company categorized its warrants potentially settleable in cash as Level 3 fair value measurements. The warrants potentially settleable in cash are measured at fair value on a recurring basis and are being marked to fair value at each reporting date until they are completely settled or meet the requirements to be accounted for as component of stockholders’ equity. The warrants are valued using the Black-Scholes option-pricing model as discussed in Note 4 below.

 

The following table presents a summary of fair values of assets and liabilities that are re-measured at fair value at each balance sheet date as of September 30, 2017 and December 31, 2016, and their placement within the fair value hierarchy as discussed above (in thousands):

 

         

Quoted

Prices in

Active

Markets

    

Significant

Other

Observable

Inputs

    

Unobservable

Inputs

  
Description   September 30, 2017     (Level 1)     (Level 2)     (Level 3)  
Assets:                                
Cash and cash equivalents   $ 1,345     $ 1,345     $        -     $          -  
Total assets   $ 1,345     $ 1,345     $ -     $ -  
                                 
Liabilities:                                
Warrants potentially settleable in cash   $ 855     $ -     $ -     $ 855  
Total liabilities   $ 855     $ -     $ -     $ 855  

 

          Quoted Prices in Active Markets    

Significant

Other 
Observable Inputs

     Unobservable Inputs  
Description   December 31, 2016     (Level 1)     (Level 2)     (Level 3)  
Assets:                                
Cash and cash equivalents   $ 3,640     $ 3,640     $      -     $         -  
Total assets   $ 3,640     $ 3,640     $ -     $ -  
                                 
Liabilities:                                
Warrants potentially settleable in cash   $ 1,476     $ -     $ -     $ 1,476  
Total liabilities   $ 1,476     $ -     $ -     $ 1,476  

 

The Company has not transferred any financial instruments into or out of Level 3 classification during the nine months ended September 30, 2017 or 2016. A reconciliation of the beginning and ending Level 3 liabilities for the nine months ended September 30, 2017 and 2016 is as follows:

 

   

Fair Value Measurements 
Using Significant Unobservable

Inputs 
(Level 3)

  
    September 30, 2017     September 30, 2016  
Balance, January 1,   $ 1,476     $ 4,115  
Estimated fair value of warrants exchanged for common shares     -       (35 )
Change in fair value of warrants     (621 )     (2,173 )
Balance at September 30, 2017 and 2016   $ 855     $ 1,907  
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity
 9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Stockholders' Equity

Note 3 – Stockholders’ equity

 

Common Stock — The Company has authorized up to 800,000,000 shares of common stock, $0.001 par value per share, and had 728,238,507 shares issued and outstanding as of September 30, 2017.

 

On April 20, 2017, the Company closed on proceeds of $3,000,000 in a private placement offering of 12,500,000 shares of the Company’s common stock at a purchase price of $0.24 per share to three accredited investors, which included Chairman Dr. Raymond F. Schinazi and OPKO Health, Inc., of which the Company’s director Dr. Phillip Frost is Chairman and Chief Executive Officer.

 

Shares of common stock authorized for future issuance as follows as of September 30, 2017 (in thousands):

 

    As of 
September 30, 2017		  
Stock options issued and outstanding     21,344  
Authorized for future option grants     49,668  
Warrants outstanding     6,275  
Total     77,287  

 

The common stock authorized for future option grants was not reserved by the Company. The Company currently does not have enough common stock authorized to issue all the options authorized by the Company for future grants.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Warrants
 9 Months Ended
Sep. 30, 2017
Warrants  
Warrants

Note 4 – Warrants

 

The following is a summary of activity in the number of warrants outstanding to purchase the Company’s common stock for the nine months ended September 30, 2017 (in thousands):

 

   

Warrants accounted for

as: Equity

    

Warrants accounted for as:

Liabilities

  
    April 2013 
warrants		     October 2013 
Series A 
warrants		     January 2014 
warrants		     Total  
                         
Outstanding, December 31, 2016     1,500       775       4,000       6,275  
                                 
Warrants expired     -       -       -       -  
Warrants exercised     -       -       -       -  
Outstanding, September 30, 2017     1,500       775       4,000       6,275  
Expiration 
date		     April 25, 2018       October 24, 2023       January 16, 2024          

 

Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.

 

Warrants classified as liabilities

 

Liability-classified warrants consist of warrants issued in connection with equity financings in October 2013 and January 2014 and potentially settleable in cash and were determined not to be indexed to the Company’s own stock and are therefore accounted for as liabilities.

 

The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of comprehensive loss as changes in fair value of derivative liabilities.

 

The Company’s expected volatility is based on a combination of implied volatilities of similar publicly traded entities given that the Company has limited history of its own observable stock price. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the balance sheet date. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.

 

The fair value of the warrants classified as liabilities is estimated using the Black-Scholes option-pricing model with the following inputs as of September 30, 2017:

 

    October 2013 warrants     January 2014 warrants  
             
Strike price   $ 0.50     $ 0.50  
                 
Expected term (years)     6.1       6.3  
Cumulative volatility %     88.00 %     89.00 %
Risk-free rate %     2.11 %     2.12 %

 

The Company’s expected volatility is based on a combination of implied volatilities of similar publicly traded entities as well as including the Company's own common stock volatility, given that the Company has limited history of its own observable stock price. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the balance sheet date. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.

 

Warrants classified as equity

 

Warrants that were recorded in equity at fair value upon issuance, and are not reported as liabilities on the balance sheet, are included in the above table which shows all warrants.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation

Note 5 – Stock-based compensation

 

The Company recorded approximately $142,000 and $409,000 of stock-based compensation related to employee stock options for the three and nine months ended September 30, 2017. For the three and nine months ended September 30, 2016, stock option expense was a ($1,138,000) and $297,000, respectively. During the third quarter of 2016, the Company reversed $1,392,000 in stock option expenses related to non-vested options issued to two executives that left the organization. Expense for the remaining employees were only $254,000, resulting in the negative stock option expense for the three months ended September 30, 2016.

 

As of September 30, 2017, there was $643,000 of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the Company’s operating expenses over a weighted average period of 1.50 years.

 

The administrator of the Company’s stock option plans determines the times when an option may become exercisable at the time of grant. Vesting periods of options granted to date have not exceeded five years. The options generally will expire, unless previously exercised, no later than ten years from the grant date. The Company is using unissued shares for all shares issued for options and restricted share awards.

 

The following schedule presents activity in the Company’s outstanding stock options for the nine months ended September 30, 2017 (in thousands, except per share amounts):

 

   

Number of shares available

for grant

    

Total

options outstanding

    

Weighted Average Exercise

Price

    

Aggregate Intrinsic

Value

  
Balance at December 31, 2016     48,368       24,351     $ 0.30     $ 5,457  
Exercised     -       (1,707 )     0.05       -  
Granted     -       -       -       -  
Cancelled     1,300       (1,300 )     0.96          
Balance at September 30, 2017     49,668       21,344     $ 0.28     $ 2,874  

 

As of September 30, 2017, options to purchase 21,344,222 shares of common stock, with an aggregate intrinsic value of $2,874,000, were outstanding that were fully vested or expected to vest with a weighted average remaining contractual term of 4.1 years. As of September 30, 2017, options to purchase 20,464,222 shares of common stock with a weighted average exercise price of $0.24 per share and a weighted average remaining contractual term of 3.6 years were fully vested with an intrinsic value of $2,874,000.

 

The aggregate intrinsic value of outstanding and exercisable options at September 30, 2017 was calculated based on the closing price of the Company’s common stock as reported on the OTCQB market on September 29, 2017 of $0.27 per share less the exercise price of the options. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Company’s common stock and the exercise price of the underlying options.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss Per Share
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Net Loss Per Share

Note 6 – Net Loss per Share

 

The Company accounts for and discloses net loss per common share in accordance with FASB ASC Topic 260, Earnings Per Share. Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants. 

 

The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands):

 

    For the three months ended
September 30		     For the nine months ended
September 30		  
    2017     2016     2017     2016  
Options to purchase common stock     21,344       24,651       21,344       24,651  
Warrants to purchase common stock     6,275       -       6,275       783  
Total     27,619       24,651       27,619       25,434  
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Mortgage Note Receivable
 9 Months Ended
Sep. 30, 2017
Receivables [Abstract]  
Mortgage Note Receivable

Note 7 - Mortgage Note Receivable

 

In June 2014, the Company acquired a mortgage note from a bank for $2,626,290 which is collateralized by, among other things, the underlying real estate and related improvements. The property subject to the mortgage is owned by an entity managed by Daniel Fisher, one of the founders of Biozone, and to the Company’s knowledge, is currently being occupied by Flavor Producers, Inc. in an instance where that company is not currently making rent payments. At September 30, 2017, the carrying amount of the mortgage note receivable was $1,294,000, consisting entirely of principal. The mortgage note has a maturity date of August 1, 2032 and bears an interest rate of 7.24%.

 

In 2014, Daniel Fisher and his affiliate, 580 Garcia Properties LLC, brought multiple lawsuits against the Company involving its predecessors and subsidiaries. The lawsuits have been settled and the complaints initiating them dismissed, without the Company making any payments to either Mr. Fisher or 580 Garcia Properties LLC. In addition, the mortgage note discussed above is a promissory note secured by a deed of trust under which 580 Garcia Properties LLC is the primary obligor. As of the time of the acquisition by the Company of the promissory note, 580 Garcia Properties LLC, was delinquent in its obligation to make certain monthly payments thereunder. Consequently, in December 2015, the Company issued notice of default letters to 580 Garcia Properties LLC, Daniel Fisher, and Sharon Fisher for said delinquencies, and proceeded in accordance with rights of a secured real estate creditor under California law, to initiate private foreclosure proceedings respecting the property, to foreclose under the promissory note secured by the deed of trust. A foreclosure sale was set in accordance with California law for January 27, 2017. Prior to the date of this foreclosure sale, Mr. Fisher filed a motion where he sought among other things an order of the court enjoining the foreclosure sale, alleging wrongdoing by the Company and Biozone Pharmaceuticals, Inc. and others that Mr. Fisher claims the Company has direct responsibility over. The court in the Fisher/Biozone Lawsuit heard oral argument on Mr. Fisher’s motion on March 2, 2017. On March 23, 2017, the court ordered further briefing by March 30, 2017 on the issue of whether to enjoin the foreclosure sale. On April 5, 2017, the court in the Fisher/Biozone Lawsuit entered a preliminary injunction barring the foreclosure sale until further order, and since that time the Company has engaged in settlement discussions with Mr. Fisher and 580 Garcia Properties LLC and others, to discuss an overall resolution of Fisher/Biozone claims of money damages allegedly caused to it by the transfer of occupants at the property, and Company efforts to either bring the promissory note to a performing status or to otherwise monetize the Company’s rights under the promissory note. The Company cannot offer any assurances as to when, or if, any settlement will be achieved, and the court has scheduled case management conferences to consider further proceedings, with the next case management conference set for November 30, 2017.

 

Because the Company intended to foreclose on the property and foreclosure was probable, in December 2016 the Company recognized an impairment on the mortgage note receivable of $1,176,000 to adjust the carrying value of the note to its fair value. The fair value of the note was determined by reference to the estimated fair value of the underlying property, which was determined based on analysis of comparable properties and recent market data. Furthermore, as a result of the Company’s plan to divest of this asset within the next twelve months, we are no longer recording interest income and the asset was reclassified from long-term to current at December 31, 2016.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
 9 Months Ended
Sep. 30, 2017
Income Tax Disclosure [Abstract]  
Income Taxes

Note 8 – Income Taxes

 

Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

 

As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. The Company has recorded a net deferred tax liability of $20,462,000 as of September 30, 2017 and December 31, 2016 as it has not considered the deferred tax liability, which is related to acquired in-process research and development, to be a future source of taxable income in evaluating the need for a valuation allowance against its deferred tax assets due to the in-process research and development asset being considered an indefinite-lived intangible asset.

 

FASB ASC Topic 740, Income Taxes (“ASC 740”), prescribes a recognition threshold and a measurement criterion for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be considered more likely than not to be sustained upon examination by taxing authorities. The Company records interest and penalties related to uncertain tax positions as a component of the provision for income taxes. As of September 30, 2017 and December 31, 2016, the Company had no unrecognized tax benefits.

 

The Company currently files income tax returns in the United States federal and various state jurisdictions. The Company is not currently under examination in any jurisdiction.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Contingencies
 9 Months Ended
Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Contingencies

Note 9 - Contingencies

 

As a publicly traded company, from time to time, the Company may be party to, or otherwise involved in, legal proceedings and inquiries from regulators arising in the normal course of business. As of the date of this report, except as described below, the Company is not aware of any proceedings, threatened or pending, against it which, if determined adversely, would have a material effect on its business, results of operations, cash flows or financial position.

 

In June 2014, the Company acquired a mortgage note from a bank, which is collateralized by, among other things, the underlying real estate and related improvements. At September 30, 2017, the carrying amount of the mortgage note receivable was $1,294,000, consisting entirely of principal. The Company is currently in legal proceedings regarding the mortgage note receivable and collateralized real estate (see Note 7).
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Transactions with Related Parties
 9 Months Ended
Sep. 30, 2017
Related Party Transactions [Abstract]  
Transactions with Related Parties

Note 10 - Transactions with Related Parties

 

Since November 2014, the Company has leased its Tucker, Georgia facility from a limited liability company owned by one of Cocrystal’s directors and principal shareholder, Dr. Raymond Schinazi. The annual expense for this lease is estimated to be $233,000. The present lease expired June 30, 2017 and the Company is currently on a month-to-month term. The total rent expense was $51,000 and $162,000 for the three and nine months ended September 30, 2017 and $59,000 and $177,000 for the three and nine months ended 2016, respectively.

 

Emory University: The Company has an exclusive license from Emory University for use of certain inventions and technology related to inhibitors of HCV that were jointly developed by Emory and Company employees. The License Agreement is dated March 7, 2013 wherein Emory agrees to add to the Licensed Patents and Licensed Technology Emory’s rights to any patent, patent application, invention, or technology application that is based on technology disclosed within three (3) years of March 7, 2013. The agreement includes payments due to Emory ranging from $40,000 to $500,000 based on successful achievement of certain drug development milestones. Additionally, the Company may have royalty payments at 3.5% of net sales due to Emory with a minimum in year one of $25,000 and increase to $400,000 in year five upon product commercialization. One of the Company’s Directors, Dr. Raymond Schinazi, is also a faculty member at Emory University and may share in these royalty payments with Emory.

 

On February 2, 2016, the Company entered into an agreement with Duke University and Emory University to license various patents and know-how to use CRISPR/Cas9 technologies for developing a possible cure for hepatitis B virus (HBV) and human papilloma virus (HPV). On September 25, 2017 (“Termination Date”), the Company mutually terminated the agreement with Duke University and there are no further rights or obligations under this license agreement after the Termination Date.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization and Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Basis of Presentation and Significant Accounting Policies

Basis of Presentation and Significant Accounting Policies

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. Operating results for the nine month period ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 or any future interim periods. All intercompany accounts and transactions have been eliminated in consolidation.

 

These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in the Cocrystal Pharma, Inc. Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the U.S. Securities and Exchange Commission (“SEC”). The accompanying condensed consolidated balance sheet as of September 30, 2017 has been derived from the audited financial statements as of that date, but does not include all of the information and notes required by GAAP.  The Company has evaluated subsequent events after the balance sheet date of September 30, 2017 through the date it has filed these unaudited condensed consolidated financial statements with the SEC and has disclosed all events or transactions that would require recognition or disclosures in these unaudited condensed consolidated financial statements.

 

Our significant accounting policies and practices are presented in Note 2 to the financial statements included in the Form 10-K.
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). ASU 2016-02 impacts any entity that enters into a lease with some specified scope exceptions. This new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The guidance updates and supersedes Topic 840, Leases. For public entities, ASU 2016-02 is effective for fiscal years, and interim periods with those years, beginning after December 15, 2018, and early adoption is permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company has not yet implemented this guidance. However, based on the Company’s current operating lease arrangements, the Company does not expect the adoption of this standard to have a material impact on its financial statements based upon current obligations.

 

In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718). This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. ASU 2016-09 also clarifies the statement of cash flows presentation for certain components of share-based awards. The Company adopted this standard as of January 1, 2017. The Company has elected to adopt the provisions of ASU No. 2016-09 that allow for stock option forfeitures to be recorded as they occur; however, adoption of this provision had no impact on its consolidated financial statements.

 

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). This standard addresses the classification of eight specific cash flow issues with the objective of reducing the existing diversity in practice. ASU 2016-15 will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.

 

In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350). This standard simplifies how an entity is required to test for goodwill impairment. ASU 2017-04 will be effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, with early adoption permitted after January 1, 2017. We are currently evaluating the impact of this new guidance on our Condensed Consolidated Financial Statements.

 

In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of future equity offerings. Current accounting guidance requires financial instruments with down round features to be accounted for at fair value. Part II of the Update applies only to nonpublic companies and is therefore not applicable to the Company. The amendments in Part I of the Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. This Update is effective for public entities for fiscal years beginning after December 15, 2018. Early adoption is permitted. The Company has not yet determined when it will adopt the provisions of this Update and has not yet determined the impact on its consolidated financial statements upon adoption.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2017
Fair Value Disclosures [Abstract]  
Summary of Fair Values of Assets and Liabilities Measured at Fair Value on Recurring and NonRecurring Basis

The following table presents a summary of fair values of assets and liabilities that are re-measured at fair value at each balance sheet date as of September 30, 2017 and December 31, 2016, and their placement within the fair value hierarchy as discussed above (in thousands):

 

         

Quoted

Prices in

Active

Markets

    

Significant

Other

Observable

Inputs

    

Unobservable

Inputs

  
Description   September 30, 2017     (Level 1)     (Level 2)     (Level 3)  
Assets:                                
Cash and cash equivalents   $ 1,345     $ 1,345     $        -     $          -  
Total assets   $ 1,345     $ 1,345     $ -     $ -  
                                 
Liabilities:                                
Warrants potentially settleable in cash   $ 855     $ -     $ -     $ 855  
Total liabilities   $ 855     $ -     $ -     $ 855  

 

          Quoted Prices in Active Markets    

Significant

Other 
Observable Inputs

     Unobservable Inputs  
Description   December 31, 2016     (Level 1)     (Level 2)     (Level 3)  
Assets:                                
Cash and cash equivalents   $ 3,640     $ 3,640     $      -     $         -  
Total assets   $ 3,640     $ 3,640     $ -     $ -  
                                 
Liabilities:                                
Warrants potentially settleable in cash   $ 1,476     $ -     $ -     $ 1,476  
Total liabilities   $ 1,476     $ -     $ -     $ 1,476  
Schedule of Reconciliation of Beginning and Ending Level 3 Liabilities

The Company has not transferred any financial instruments into or out of Level 3 classification during the nine months ended September 30, 2017 or 2016. A reconciliation of the beginning and ending Level 3 liabilities for the nine months ended September 30, 2017 and 2016 is as follows:

 

   

Fair Value Measurements 
Using Significant Unobservable

Inputs 
(Level 3)

  
    September 30, 2017     September 30, 2016  
Balance, January 1,   $ 1,476     $ 4,115  
Estimated fair value of warrants exchanged for common shares     -       (35 )
Change in fair value of warrants     (621 )     (2,173 )
Balance at September 30, 2017 and 2016   $ 855     $ 1,907  
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Schedule of Shares of Common Stock Authorized for Future Issuance

Shares of common stock authorized for future issuance as follows as of September 30, 2017 (in thousands):

 

    As of 
September 30, 2017		  
Stock options issued and outstanding     21,344  
Authorized for future option grants     49,668  
Warrants outstanding     6,275  
Total     77,287  
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Warrants (Tables)
 9 Months Ended
Sep. 30, 2017
Warrants  
Summary of Warrant Activity

The following is a summary of activity in the number of warrants outstanding to purchase the Company’s common stock for the nine months ended September 30, 2017 (in thousands):

 

   

Warrants accounted for

as: Equity

    

Warrants accounted for as:

Liabilities

  
    April 2013 
warrants		     October 2013 
Series A 
warrants		     January 2014 
warrants		     Total  
                         
Outstanding, December 31, 2016     1,500       775       4,000       6,275  
                                 
Warrants expired     -       -       -       -  
Warrants exercised     -       -       -       -  
Outstanding, September 30, 2017     1,500       775       4,000       6,275  
Expiration 
date		     April 25, 2018       October 24, 2023       January 16, 2024          
Schedule of Fair Value of Warrants Classified as Liabilities

The fair value of the warrants classified as liabilities is estimated using the Black-Scholes option-pricing model with the following inputs as of September 30, 2017:

 

    October 2013 warrants     January 2014 warrants  
             
Strike price   $ 0.50     $ 0.50  
                 
Expected term (years)     6.1       6.3  
Cumulative volatility %     88.00 %     89.00 %
Risk-free rate %     2.11 %     2.12 %
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Share-based Compensation, Stock Options, Activity

The following schedule presents activity in the Company’s outstanding stock options for the nine months ended September 30, 2017 (in thousands, except per share amounts):

 

   

Number of shares available

for grant

    

Total

options outstanding

    

Weighted Average Exercise

Price

    

Aggregate Intrinsic

Value

  
Balance at December 31, 2016     48,368       24,351     $ 0.30     $ 5,457  
Exercised     -       (1,707 )     0.05       -  
Granted     -       -       -       -  
Cancelled     1,300       (1,300 )     0.96          
Balance at September 30, 2017     49,668       21,344     $ 0.28     $ 2,874  
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Calculations of Net Loss Per Share

The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands):

 

    For the three months ended
September 30		     For the nine months ended
September 30		  
    2017     2016     2017     2016  
Options to purchase common stock     21,344       24,651       21,344       24,651  
Warrants to purchase common stock     6,275       -       6,275       783  
Total     27,619       24,651       27,619       25,434  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization and Significant Accounting Policies (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Accounting Policies [Abstract]          
Accumulated deficit $ 143,240   $ 143,240   $ 137,430
Loss from operations $ 2,110 $ 1,894 6,430 $ 11,433  
Cash used in operating activities     $ 5,323 $ 12,354  
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurement - Summary of Fair Values of Assets and Liabilities Measured at Fair Value On Recurring and NonRecurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Sep. 30, 2016
Dec. 31, 2015
Cash and cash equivalents $ 1,345 $ 3,640 $ 5,906 $ 9,276
Total assets 1,345 3,640    
Warrants potentially settleable in cash 855 1,476    
Total liabilities 855 1,476    
Quoted Prices in Active Markets Level 1 [Member]        
Cash and cash equivalents 1,345 3,640    
Total assets 1,345 3,640    
Warrants potentially settleable in cash    
Total liabilities    
Significant Other Observable Inputs Level 2 [Member]        
Cash and cash equivalents    
Total assets    
Warrants potentially settleable in cash    
Total liabilities    
Unobservable Inputs Level 3 [Member]        
Cash and cash equivalents    
Total assets    
Warrants potentially settleable in cash 855 1,476    
Total liabilities $ 855 $ 1,476    
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Schedule of Reconciliation of the Beginning and Ending Level 3 Liabilities (Details) - Unobservable Inputs Level 3 [Member] - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Balance - January 1 $ 1,476 $ 4,115
Estimated fair value of warrants exchanged for common shares (35)
Change in fair value of warrants (621) (2,173)
Balance at September 30, 2017 and 2016 $ 855 $ 1,907
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholder's Equity (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Apr. 20, 2017
Sep. 30, 2017
Dec. 31, 2016
Common stock authorized   800,000,000 800,000,000
Common stock par value   $ 0.001 $ 0.001
Common stock issued   728,239,000 714,032,000
Common stock outstanding   728,239,000 714,032,000
Number of common stock issued   $ 3,000  
Private Placement [Member] | Three Accredited Investor [Member]      
Number of common stock issued $ 3,000    
Number of common stock issued, shares 12,500,000    
Common stock purchase price, per share $ 0.24    
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Equity - Schedule of Shares of Common Stock Authorized for Future Issuance (Details)
Sep. 30, 2017
shares
Equity [Abstract]  
Stock options issued and outstanding 21,344,000
Authorized for future option grants 49,668,000
Warrants outstanding 6,275,000
Total 77,287,000
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Warrants (Details Narrative)
 9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Risk free interest 0.00%
Dividend Yield 0.00%
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Warrants - Summary of Warrant Activity (Details)
 9 Months Ended
Sep. 30, 2017
shares
Warrants to Purchase Common Stock [Member]  
Number of warrants outstanding, beginning 6,275,000
Number of warrants expired
Number of warrants exercised
Number of warrants outstanding, ending 6,275,000
April 2013 Warrants [Member] | Equity [Member]  
Number of warrants outstanding, beginning 1,500,000
Number of warrants expired
Number of warrants exercised
Number of warrants outstanding, ending 1,500,000
Warrant expiration date Apr. 25, 2018
October 2013 Series A Warrants [Member] | Liabilities [Member]  
Number of warrants outstanding, beginning 775,000
Number of warrants expired
Number of warrants exercised
Number of warrants outstanding, ending 775,000
Warrant expiration date Oct. 24, 2023
January 2014 Warrants [Member] | Liabilities [Member]  
Number of warrants outstanding, beginning 4,000,000
Number of warrants expired
Number of warrants exercised
Number of warrants outstanding, ending 4,000,000
Warrant expiration date Jan. 16, 2024
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Warrants - Schedule of Fair Value of Warrants Classified as Liabilities (Details)
 9 Months Ended
Sep. 30, 2017
$ / shares
Strike price $ 0.27
Risk-free rate % 0.00%
October 2013 Warrants [Member]  
Strike price $ 0.50
Expected term (years) 6 years 1 month 6 days
Cumulative volatility % 88.00%
Risk-free rate % 2.11%
January 2014 Warrants [Member]  
Strike price $ 0.50
Expected term (years) 6 years 3 months 19 days
Cumulative volatility % 89.00%
Risk-free rate % 2.12%
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock-Based Compensation (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Stock-based compensation related to employee $ 142 $ (1,138) $ 409 $ 297
Unrecognized compensation cost related to outstanding options $ 643   $ 643  
Weighted average period     1 year 6 months  
Stock based compensation vesting description     Vesting periods of options granted to date have not exceeded five years. The options generally will expire, unless previously exercised, no later than ten years from the grant date.  
Stock option to purchase common stock vested or expected to vest 21,344,222   21,344,222  
Aggregate intrinsic value vested or expected to be vest $ 2,874   $ 2,874  
Stock option vesting period     4 years 1 month 6 days  
Stock option to purchase common stock 20,464,222   20,464,222  
Weighted average exercise price $ 0.24   $ 0.24  
Weighted average contractual term     3 years 7 months 6 days  
Aggregate intrinsic value $ 2,874   $ 2,874  
Share price $ 0.27   $ 0.27  
Two Executives [Member]        
Stock option expense       $ 1,392
Employees [Member]        
Stock option expense   $ 254    
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stock-Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details)
$ / shares in Units, $ in Thousands
 9 Months Ended
Sep. 30, 2017
USD ($)
$ / shares
shares
Number of shares available for grant, ending 49,668,000
Total options outstanding, ending 21,344,222
Aggregate Intrinsic Value, ending | $ $ 2,874
Warrants to Purchase Common Stock [Member]  
Number of shares available for grant, beginning 48,368,000
Number of shares available for grant, Exercised
Number of shares available for grant, Granted
Number of shares available for grant, Cancelled 1,300,000
Number of shares available for grant, ending 49,668,000
Total options outstanding, beginning 24,351,000
Total options outstanding, Exercised (1,707,000)
Total options outstanding, Granted
Total options outstanding, Cancelled (1,300,000)
Total options outstanding, ending 21,344,000
Weighted Average Exercise Price, outstanding | $ / shares $ 0.30
Weighted Average Exercise Price, Exercised | $ / shares 0.05
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares 0.96
Weighted Average Exercise Price, ending | $ / shares $ 0.28
Aggregate Intrinsic Value, outstanding | $ $ 5,457
Aggregate Intrinsic Value, ending | $ $ 2,874
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculations of Net Loss Per Share (Details) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Anti-dilutive securities 27,619,000 24,651,000 27,619,000 25,434,000
Options to Purchase Common Stock [Member]        
Anti-dilutive securities 21,344,000 24,651,000 21,344,000 24,651,000
Warrants to Purchase Common Stock [Member]        
Anti-dilutive securities 6,275,000 6,275,000 783,000
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Mortgage Note Receivable (Details Narrative) - USD ($)
 1 Months Ended
Dec. 31, 2016
Sep. 30, 2014
Sep. 30, 2017
Jun. 30, 2014
Mortgage note receivable $ 1,294,000   $ 1,294,000  
Mortgage Note [Member]        
Mortgage note receivable       $ 2,626,290
Debt instrument maturity date   Aug. 01, 2032    
Debt instrument interest rate       7.24%
Impairment of mortgage note receivable $ 1,176,000      
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Details Narrative) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Income Tax Disclosure [Abstract]    
Net deferred tax liability $ 20,462 $ 20,462
Unrecognized tax benefits
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Contingencies (Details Narrative) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]    
Carrying amount of mortgage note receivable $ 1,294 $ 1,294
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Transactions with Related Parties (Details Narrative) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Nov. 30, 2014
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Rent expenses   $ 51 $ 59 $ 162 $ 177
Royalty payment rate   3.50%   3.50%  
License Agreement [Member] | One Year [Member]          
Royalty payable   $ 25   $ 25  
License Agreement [Member] | Five Year [Member]          
Royalty payable   400   400  
Minimum [Member] | License Agreement [Member]          
Royalty payable   40   40  
Maximum [Member] | License Agreement [Member]          
Royalty payable   $ 500   $ 500  
Dr. Raymond Schinazi [Member]          
Annual lease expense $ 233        
Lease expiration Jun. 30, 2017        
EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 49 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 64 146 1 false 25 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://cocrystalpharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://cocrystalpharma.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://cocrystalpharma.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://cocrystalpharma.com/role/StatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://cocrystalpharma.com/role/StatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://cocrystalpharma.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Significant Accounting Policies Sheet http://cocrystalpharma.com/role/OrganizationAndSignificantAccountingPolicies Organization and Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Fair Value Measurements Sheet http://cocrystalpharma.com/role/FairValueMeasurements Fair Value Measurements Notes 8 false false R9.htm 00000009 - Disclosure - Stockholders' Equity Sheet http://cocrystalpharma.com/role/StockholdersEquity Stockholders' Equity Notes 9 false false R10.htm 00000010 - Disclosure - Warrants Sheet http://cocrystalpharma.com/role/Warrants Warrants Notes 10 false false R11.htm 00000011 - Disclosure - Stock-Based Compensation Sheet http://cocrystalpharma.com/role/Stock-basedCompensation Stock-Based Compensation Notes 11 false false R12.htm 00000012 - Disclosure - Net Loss Per Share Sheet http://cocrystalpharma.com/role/NetLossPerShare Net Loss Per Share Notes 12 false false R13.htm 00000013 - Disclosure - Mortgage Note Receivable Sheet http://cocrystalpharma.com/role/MortgageNoteReceivable Mortgage Note Receivable Notes 13 false false R14.htm 00000014 - Disclosure - Income Taxes Sheet http://cocrystalpharma.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 00000015 - Disclosure - Contingencies Sheet http://cocrystalpharma.com/role/Contingencies Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Transactions with Related Parties Sheet http://cocrystalpharma.com/role/TransactionsWithRelatedParties Transactions with Related Parties Notes 16 false false R17.htm 00000017 - Disclosure - Organization and Significant Accounting Policies (Policies) Sheet http://cocrystalpharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies Organization and Significant Accounting Policies (Policies) Policies http://cocrystalpharma.com/role/OrganizationAndSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Fair Value Measurements (Tables) Sheet http://cocrystalpharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://cocrystalpharma.com/role/FairValueMeasurements 18 false false R19.htm 00000019 - Disclosure - Stockholders' Equity (Tables) Sheet http://cocrystalpharma.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://cocrystalpharma.com/role/StockholdersEquity 19 false false R20.htm 00000020 - Disclosure - Warrants (Tables) Sheet http://cocrystalpharma.com/role/WarrantsTables Warrants (Tables) Tables http://cocrystalpharma.com/role/Warrants 20 false false R21.htm 00000021 - Disclosure - Stock-Based Compensation (Tables) Sheet http://cocrystalpharma.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://cocrystalpharma.com/role/Stock-basedCompensation 21 false false R22.htm 00000022 - Disclosure - Net Loss Per Share (Tables) Sheet http://cocrystalpharma.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://cocrystalpharma.com/role/NetLossPerShare 22 false false R23.htm 00000023 - Disclosure - Organization and Significant Accounting Policies (Details Narrative) Sheet http://cocrystalpharma.com/role/OrganizationAndSignificantAccountingPoliciesDetailsNarrative Organization and Significant Accounting Policies (Details Narrative) Details http://cocrystalpharma.com/role/OrganizationAndSignificantAccountingPoliciesPolicies 23 false false R24.htm 00000024 - Disclosure - Fair Value Measurement - Summary of Fair Values of Assets and Liabilities Measured at Fair Value On Recurring and NonRecurring Basis (Details) Sheet http://cocrystalpharma.com/role/FairValueMeasurement-SummaryOfFairValuesOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonrecurringBasisDetails Fair Value Measurement - Summary of Fair Values of Assets and Liabilities Measured at Fair Value On Recurring and NonRecurring Basis (Details) Details 24 false false R25.htm 00000025 - Disclosure - Fair Value Measurements - Schedule of Reconciliation of the Beginning and Ending Level 3 Liabilities (Details) Sheet http://cocrystalpharma.com/role/FairValueMeasurements-ScheduleOfReconciliationOfBeginningAndEndingLevel3LiabilitiesDetails Fair Value Measurements - Schedule of Reconciliation of the Beginning and Ending Level 3 Liabilities (Details) Details 25 false false R26.htm 00000026 - Disclosure - Stockholder's Equity (Details Narrative) Sheet http://cocrystalpharma.com/role/StockholdersEquityDetailsNarrative Stockholder's Equity (Details Narrative) Details 26 false false R27.htm 00000027 - Disclosure - Stockholders' Equity - Schedule of Shares of Common Stock Authorized for Future Issuance (Details) Sheet http://cocrystalpharma.com/role/StockholdersEquity-ScheduleOfSharesOfCommonStockAuthorizedForFutureIssuanceDetails Stockholders' Equity - Schedule of Shares of Common Stock Authorized for Future Issuance (Details) Details 27 false false R28.htm 00000028 - Disclosure - Warrants (Details Narrative) Sheet http://cocrystalpharma.com/role/WarrantsDetailsNarrative Warrants (Details Narrative) Details http://cocrystalpharma.com/role/WarrantsTables 28 false false R29.htm 00000029 - Disclosure - Warrants - Summary of Warrant Activity (Details) Sheet http://cocrystalpharma.com/role/Warrants-SummaryOfWarrantActivityDetails Warrants - Summary of Warrant Activity (Details) Details 29 false false R30.htm 00000030 - Disclosure - Warrants - Schedule of Fair Value of Warrants Classified as Liabilities (Details) Sheet http://cocrystalpharma.com/role/Warrants-ScheduleOfFairValueOfWarrantsClassifiedAsLiabilitiesDetails Warrants - Schedule of Fair Value of Warrants Classified as Liabilities (Details) Details 30 false false R31.htm 00000031 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://cocrystalpharma.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://cocrystalpharma.com/role/Stock-basedCompensationTables 31 false false R32.htm 00000032 - Disclosure - Stock-Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details) Sheet http://cocrystalpharma.com/role/Stock-basedCompensation-ScheduleOfShare-basedCompensationStockOptionsActivityDetails Stock-Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details) Details 32 false false R33.htm 00000033 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculations of Net Loss Per Share (Details) Sheet http://cocrystalpharma.com/role/NetLossPerShare-ScheduleOfAntidilutiveSecuritiesExcludedFromCalculationsOfNetLossPerShareDetails Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Calculations of Net Loss Per Share (Details) Details 33 false false R34.htm 00000034 - Disclosure - Mortgage Note Receivable (Details Narrative) Sheet http://cocrystalpharma.com/role/MortgageNoteReceivableDetailsNarrative Mortgage Note Receivable (Details Narrative) Details http://cocrystalpharma.com/role/MortgageNoteReceivable 34 false false R35.htm 00000035 - Disclosure - Income Taxes (Details Narrative) Sheet http://cocrystalpharma.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://cocrystalpharma.com/role/IncomeTaxes 35 false false R36.htm 00000036 - Disclosure - Contingencies (Details Narrative) Sheet http://cocrystalpharma.com/role/ContingenciesDetailsNarrative Contingencies (Details Narrative) Details http://cocrystalpharma.com/role/Contingencies 36 false false R37.htm 00000037 - Disclosure - Transactions with Related Parties (Details Narrative) Sheet http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative Transactions with Related Parties (Details Narrative) Details http://cocrystalpharma.com/role/TransactionsWithRelatedParties 37 false false All Reports Book All Reports cocp-20170930.xml cocp-20170930.xsd cocp-20170930_cal.xml cocp-20170930_def.xml cocp-20170930_lab.xml cocp-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 54 0001493152-17-012612-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-17-012612-xbrl.zip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end